AU2018271862B2 - Combination therapy - Google Patents
Combination therapy Download PDFInfo
- Publication number
- AU2018271862B2 AU2018271862B2 AU2018271862A AU2018271862A AU2018271862B2 AU 2018271862 B2 AU2018271862 B2 AU 2018271862B2 AU 2018271862 A AU2018271862 A AU 2018271862A AU 2018271862 A AU2018271862 A AU 2018271862A AU 2018271862 B2 AU2018271862 B2 AU 2018271862B2
- Authority
- AU
- Australia
- Prior art keywords
- certain embodiments
- substituents
- optionally substituted
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002648 combination therapy Methods 0.000 title abstract description 35
- 239000003112 inhibitor Substances 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 82
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 239000012271 PD-L1 inhibitor Substances 0.000 claims abstract description 31
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims abstract description 31
- 239000012270 PD-1 inhibitor Substances 0.000 claims abstract description 29
- 239000012668 PD-1-inhibitor Substances 0.000 claims abstract description 29
- 229940121655 pd-1 inhibitor Drugs 0.000 claims abstract description 29
- 125000001424 substituent group Chemical group 0.000 claims description 455
- -1 heteroalkenylene Chemical group 0.000 claims description 425
- 150000001875 compounds Chemical class 0.000 claims description 332
- 229910052739 hydrogen Inorganic materials 0.000 claims description 293
- 239000001257 hydrogen Substances 0.000 claims description 293
- 125000000217 alkyl group Chemical group 0.000 claims description 228
- 125000000623 heterocyclic group Chemical group 0.000 claims description 206
- 125000003118 aryl group Chemical group 0.000 claims description 178
- 125000001072 heteroaryl group Chemical group 0.000 claims description 171
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 147
- 230000000155 isotopic effect Effects 0.000 claims description 137
- 239000012453 solvate Substances 0.000 claims description 132
- 229940002612 prodrug Drugs 0.000 claims description 130
- 239000000651 prodrug Substances 0.000 claims description 130
- 150000003839 salts Chemical class 0.000 claims description 130
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 117
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 103
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 96
- 125000004432 carbon atom Chemical group C* 0.000 claims description 86
- 125000005843 halogen group Chemical group 0.000 claims description 83
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 81
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 81
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 53
- 239000012828 PI3K inhibitor Substances 0.000 claims description 51
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 51
- 229910052799 carbon Inorganic materials 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 125000002947 alkylene group Chemical group 0.000 claims description 27
- 229950002916 avelumab Drugs 0.000 claims description 27
- 229960000106 biosimilars Drugs 0.000 claims description 27
- 229960003301 nivolumab Drugs 0.000 claims description 27
- 229960002621 pembrolizumab Drugs 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 26
- 229960003852 atezolizumab Drugs 0.000 claims description 25
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 23
- 229950009791 durvalumab Drugs 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 17
- 125000004450 alkenylene group Chemical group 0.000 claims description 15
- 229950010773 pidilizumab Drugs 0.000 claims description 14
- 229950007213 spartalizumab Drugs 0.000 claims description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 11
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 7
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 229910052702 rhenium Inorganic materials 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims 2
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 41
- 201000010099 disease Diseases 0.000 abstract description 26
- 108091007960 PI3Ks Proteins 0.000 abstract description 5
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 235000002639 sodium chloride Nutrition 0.000 description 119
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 103
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 93
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 93
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 48
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 47
- 150000001721 carbon Chemical group 0.000 description 47
- 125000003386 piperidinyl group Chemical group 0.000 description 47
- 125000002883 imidazolyl group Chemical group 0.000 description 46
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 46
- 125000004193 piperazinyl group Chemical group 0.000 description 46
- 125000004076 pyridyl group Chemical group 0.000 description 46
- 239000008194 pharmaceutical composition Substances 0.000 description 38
- 239000004215 Carbon black (E152) Substances 0.000 description 37
- 229930195733 hydrocarbon Natural products 0.000 description 37
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 31
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 30
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 30
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 30
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 30
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 30
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 30
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 30
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 30
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 30
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 30
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 30
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 30
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 30
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 26
- 125000000714 pyrimidinyl group Chemical group 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 17
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 17
- 206010066476 Haematological malignancy Diseases 0.000 description 17
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 17
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 17
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 17
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 17
- 208000009956 adenocarcinoma Diseases 0.000 description 16
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 16
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 125000001153 fluoro group Chemical group F* 0.000 description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 125000001246 bromo group Chemical group Br* 0.000 description 13
- 125000001309 chloro group Chemical group Cl* 0.000 description 13
- 125000002346 iodo group Chemical group I* 0.000 description 13
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 13
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 9
- 238000011284 combination treatment Methods 0.000 description 9
- 230000036210 malignancy Effects 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 208000007452 Plasmacytoma Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 208000009527 Refractory anemia Diseases 0.000 description 4
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229940066453 tecentriq Drugs 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical group O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 3
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical group O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010058207 Anistreplase Proteins 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical group NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229960003445 idelalisib Drugs 0.000 description 3
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical group SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- WKBOTKDWSSQWDR-AHCXROLUSA-N Bromine-79 Chemical compound [76Br] WKBOTKDWSSQWDR-AHCXROLUSA-N 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 2
- OAICVXFJPJFONN-NJFSPNSNSA-N Phosphorus-33 Chemical compound [33P] OAICVXFJPJFONN-NJFSPNSNSA-N 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-NJFSPNSNSA-N Sulfur-34 Chemical compound [34S] NINIDFKCEFEMDL-NJFSPNSNSA-N 0.000 description 2
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 2
- NINIDFKCEFEMDL-RNFDNDRNSA-N Sulfur-36 Chemical compound [36S] NINIDFKCEFEMDL-RNFDNDRNSA-N 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- RWSOTUBLDIXVET-IGMARMGPSA-N ac1l2y5t Chemical compound [32SH2] RWSOTUBLDIXVET-IGMARMGPSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- 239000000464 adrenergic agent Substances 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- CPELXLSAUQHCOX-OUBTZVSYSA-N bromine-81 Chemical compound [81BrH] CPELXLSAUQHCOX-OUBTZVSYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- VEXZGXHMUGYJMC-OUBTZVSYSA-N chlorane Chemical compound [36ClH] VEXZGXHMUGYJMC-OUBTZVSYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-IGMARMGPSA-N chlorine-35 Chemical compound [35ClH] VEXZGXHMUGYJMC-IGMARMGPSA-N 0.000 description 2
- 229960004588 cilostazol Drugs 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 206010022694 intestinal perforation Diseases 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- ZCYVEMRRCGMTRW-NJFSPNSNSA-N iodine-129 atom Chemical compound [129I] ZCYVEMRRCGMTRW-NJFSPNSNSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229940097886 phosphorus 32 Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- NINIDFKCEFEMDL-OUBTZVSYSA-N sulfur-33 atom Chemical compound [33S] NINIDFKCEFEMDL-OUBTZVSYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003558 transferase inhibitor Substances 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 208000035821 Benign schwannoma Diseases 0.000 description 1
- 206010058956 Bicytopenia Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101150091609 CD274 gene Proteins 0.000 description 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930183931 Filipin Natural products 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 1
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073086 Iris melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 241000820057 Ithone Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 102100026171 P2Y purinoceptor 12 Human genes 0.000 description 1
- 101150087384 PDCD1 gene Proteins 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- AWGBZRVEGDNLDZ-UHFFFAOYSA-N Rimocidin Natural products C1C(C(C(O)C2)C(O)=O)OC2(O)CC(O)CCCC(=O)CC(O)C(CC)C(=O)OC(CCC)CC=CC=CC=CC=CC1OC1OC(C)C(O)C(N)C1O AWGBZRVEGDNLDZ-UHFFFAOYSA-N 0.000 description 1
- AWGBZRVEGDNLDZ-JCUCCFEFSA-N Rimocidine Chemical compound O([C@H]1/C=C/C=C/C=C/C=C/C[C@H](OC(=O)[C@@H](CC)[C@H](O)CC(=O)CCC[C@H](O)C[C@@]2(O)O[C@H]([C@@H]([C@@H](O)C2)C(O)=O)C1)CCC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O AWGBZRVEGDNLDZ-JCUCCFEFSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 231100000632 Spindle poison Toxicity 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000018420 bone fibrosarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 102220006545 c.1035C>A Human genes 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000002946 cyanobenzyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 229950000152 filipin Drugs 0.000 description 1
- IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 1
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
- 229950006480 gemopatrilat Drugs 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 description 1
- 229950004274 ifetroban Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005995 isobenzotetrahydrothienyl group Chemical group 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229960001788 muzolimine Drugs 0.000 description 1
- RLWRMIYXDPXIEX-UHFFFAOYSA-N muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000004624 phenarsazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3[As]=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 206010035059 pineocytoma Diseases 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940073095 questran Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 1
- 229950004154 ravuconazole Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 102200085639 rs104886003 Human genes 0.000 description 1
- 102200085623 rs1057519925 Human genes 0.000 description 1
- 102200085644 rs1057519930 Human genes 0.000 description 1
- 102220198249 rs1057519936 Human genes 0.000 description 1
- 102200085622 rs121913272 Human genes 0.000 description 1
- 102200085641 rs121913273 Human genes 0.000 description 1
- 102200085635 rs121913274 Human genes 0.000 description 1
- 102200085637 rs121913274 Human genes 0.000 description 1
- 102200085788 rs121913279 Human genes 0.000 description 1
- 102200085789 rs121913279 Human genes 0.000 description 1
- 102200085790 rs121913281 Human genes 0.000 description 1
- 102200085792 rs121913286 Human genes 0.000 description 1
- 102220289023 rs1553826166 Human genes 0.000 description 1
- 102220243971 rs369149696 Human genes 0.000 description 1
- 102200156860 rs387906985 Human genes 0.000 description 1
- 102200085793 rs397517201 Human genes 0.000 description 1
- 102200085697 rs772110575 Human genes 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- AGHANLSBXUWXTB-UHFFFAOYSA-N tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 description 1
- 229960000356 tienilic acid Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000008662 verrucous carcinoma Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
Description
COMBINATION THERAPY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Patent Application No. 62/510,204, filed on May 23, 2017, and U.S. Patent Application No. 62/518,359, filed on June 12, 2017, which are all hereby incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION
[0002] Phosphoinositide-3-kinases (PBKs) play a variety of roles in normal tissue physiology (Foukas & Shepherd, Biochem. Soc. Trans. 2004, 32, 330; Shepherd, Acta Physiol. Scand. 2005, 183, 3), with p i 10a having a specific role in cancer growth, p i 10β in thrombus formation mediated by integrin απβ3 (Jackson et al. , Nat. Med. 2005, 11, 507), and p l lOy, in inflammation, rheumatoid arthritis, and other chronic inflammation states (Barber et al. , Nat. Med. 2005, 11, 933; Camps et al. , Nat. Med. 2005, 11, 936;
Rommel et al , Nat. Rev. 2007, 7, 191; and Ito, et al. , J. Pharm. Exp. Therap. 2007, 321, 1). Inhibitors of PBKs have therapeutic potential in the treatment of various proliferative diseases, including cancer.
SUMMARY OF THE DISCLOSURE INVENTION
[0003] Disclosed herein is a method for treating or preventing a disease comprising administering:
(i) an effective amount of a compound of Formula (I) :
Formula (I),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) d_6 alkyl, C2_6
alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_¾ alkyl, C2_¾ alkenyl, C2_¾ alkynyl, C3_io cycloalkyl, C¾_i4 aryl, C7_15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, - C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, - OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, - NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, - NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)n-(C6_14 aryl) or -(CR5fR5g)n-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_i0 cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, Rx, Rla, Rlb, Rlc, Rld,
R5a, R5b, R5c, R5d, R5e, R5f, and R5g is optionally substituted with one, two, three, four, or five substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; and (c) - C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, and -S(0)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one, two, three, or four substituents Qa;
wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl; and (c) -C(0)Re, -C(0)ORe, -C(0)NRfRg, -C(NRe)NRfRg, -ORe, - OC(0)Re, -OC(0)ORe, -OC(0)NRfRg, -OC(=NRe)NRfRg, -OS(0)Re, -OS(0)2Re, -OS(0)NRfRg, - OS(0)2NRfRg, -NRfRg, -NReC(0)Rh, -NReC(0)ORh, -NReC(0)NRfRg, -NReC(=NRh)NRfRg, - NReS(0)Rh, -NReS(0)2Rh, -NReS(0)NRfRg, -NReS(0)2NRfRg, -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg, and -S(0)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl; or
wherein two substituents Q that are adjacent to each other optionally form a C3_io cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa; and
(ii) an effective amount of a PD-1 inhibitor or PD-L1 inhibitor to a patient.
[0004] In some embodiments, R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_14 aryl, C7_15 aralkyl, or heteroaryl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -S(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc.
[0005] In some embodiments, R5a and R5b are each independently (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_ 6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, - C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc.
[0006] In some embodiments, R5a and R5b are each methyl, optionally substituted with one, two or three halo(s). In some embodiments, n is 1. In some embodiments, n is 1 and R5f and R5g are each hydrogen. In some embodiments, n is 0. In some embodiments, m is 0.
[0007] In some embodiments, the compound of Formula (I) is of Formula (XI):
Formula (XI),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R7a, R^, R7c, R7d, and R7e are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; or (c) -C(0)Ra, - C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, or -S(0)2NRbRc; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form a C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa.
[0008] In some embodiments, the c und I:
Compound I,
an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0009] In some embodiments, the compound of Formula (I) is Compound II:
Compound II,
an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0010] In some embodiments, the und III:
Compound III,
an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0011] In some embodiments, the compound of Formula (I) is Compound IV:
Compound IV.
an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0012] In some embodiments, the compound of Formula (I) is Compound V:
Compound V,
an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0013] In some embodiments, the PD-1 or PD-L1 inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, durvalumab or a combination thereof. In some embodiments, the PD-1 or PD-L1 inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS- 936559, BGB-A317, PDR001, REGN2810, durvalumab or a combination thereof.
[0014] In some embodiments, the disease being treated is cancer.
INCORPORATION BY REFERENCE
[0015] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0017] FIG. 1 illustrates the Kaplan-Meier survival curves obtained from Example 2a, wherein a study was performed evaluating the efficacy of a combination treatment of Compound I and a PD-1 inhibitor (RPMl-14), in a MC38 murine adenocarcinoma model. The figure depicts the efficacy of two cycles of the combination treatment in comparison to a single cycle of a combination treatment or a single cycle of the PD-1 inhibitor.
[0018] FIG. 2 illustrates the Kaplan-Meier survival curves obtained from Example 2a, wherein a study was performed evaluating the efficacy of a combination treatment of Compound I and the PD-1 inhibitor (RPMl-14) in a MC38 murine adenocarcinoma model. The figure depicts the efficacy of two cycles of the combination treatment in comparison to a single cycle of a combination treatment or a single cycle of the combination with an additional cycle of Compound I.
[0019] FIG. 3 illustrates the Kaplan-Meier survival curves obtained from Example 2a, wherein a study was performed evaluating the efficacy of a combination treatment of Compound I and the PD-1 inhibitor (RPMl-14) in a MC38 murine adenocarcinoma model. The figure depicts the efficacy of two cycles of the
combination treatment in comparison to a single cycle of a combination treatment or a single cycle of the combination with an additional cycle of the PD-1 inhibitor.
DETAILED DESCRIPTION OF THE INVENTION
[0020] Described herein are pharmaceutical compositions comprising a PI3K inhibitor and a PD-1 or a PD-L1 inhibitor. In some instances, the pharmaceutical compositions described herein may be used for treating diseases or disorders associated with excessive cell proliferation, such as cancer. Also described herein are methods of treating the proliferative diseases and disorders with i) a PI3K inhibitor; and ii) a PD-1 or a PD-L1 inhibitor.
Definitions
[0021] To facilitate understanding of the disclosure set forth herein, a number of terms are defined below.
[0022] Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The term "subject" refers to an animal, including, but not limited to, a primate (e.g., human), cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject, in one embodiment, a human.
[0023] The terms "treat," "treating," and "treatment" are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself.
[0024] The terms "prevent," "preventing," and "prevention" are meant to include a method of delaying and/or precluding the onset of a disorder, disease, or condition, and/or its attendant symptoms; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject's risk of acquiring a disorder, disease, or condition.
[0025] The terms "therapeutically effective amount" and "effective amount" are meant to include the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated. The terms "therapeutically effective amount" or "effective amount" also refer to the amount of a compound that is sufficient to elicit the biological or medical response of a biological molecule (e.g., a protein, enzyme, RNA, or DNA), cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.
[0026] The terms "pharmaceutically acceptable carrier," "pharmaceutically acceptable excipient," "physiologically acceptable carrier," and "physiologically acceptable excipient" refer to a
pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. In one embodiment, each component is "pharmaceutically acceptable"
in the sense of being compatible with other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio. See, Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 5th Edition, Rowe et al , Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and
Handbook of Pharmaceutical Additives, 3rd Edition, Ash and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd Edition, Gibson Ed., CRC Press LLC: Boca Raton, FL, 2009.
[0027] The terms "about" and "approximately" mean an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the terms "about" and "approximately" mean within 1, 2, 3, or 4 standard deviations. In certain embodiments, the terms "about" and "approximately" mean within 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.
[0028] The terms "active ingredient" and "active substance" refer to a compound, which is administered, alone or in combination with one or more pharmaceutically acceptable excipients, to a subject for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition. As used herein, "active ingredient" and "active substance" may be an optically active isomer of a compound described herein.
[0029] The terms "drug," "therapeutic agent," and "chemotherapeutic agent" refer to a compound, or a pharmaceutical composition thereof, which is administered to a subject for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition.
[0030] The terms "naturally occurring" and "native" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refer to materials which are found in nature and are not manipulated by man. Similarly, "non-naturally occurring" or "non-native" refers to a material that is not found in nature or that has been structurally modified or synthesized by man.
[0031] The term "PI3K" refers to a phosphoinositide 3-kinase or variant thereof, which is capable of phosphorylating the inositol ring of PI in the D-3 position. The term "PI3K variant" is intended to include proteins substantially homologous to a native PI3K, i.e., proteins having one or more naturally or non- naturally occurring amino acid deletions, insertions, or substitutions (e.g., PI3K derivatives, homologs, and fragments), as compared to the amino acid sequence of a native PI3K. The amino acid sequence of a PI3K variant is at least about 80% identical, at least about 90% identical, or at least about 95% identical to a native PI3K. Examples of PI3K include, but are not limited to, pi 10a, pi 10β, pi 10δ, pi 10γ, PI3K-C2a, PI3K-C2P, PI3K-C2y, Vps34, mTOR, ATM, ATR, and DNA-PK. See, Fry, Biochem. Biophys. Acta 1994, 1226, 237-268; Vanhaesebroeck and Waterfield, Exp. Cell. Res. 1999, 253, 239-254; and Fry, Breast Cancer Res. 2001, 3, 304-312. PI3Ks are classified into at least four classes. Class I includes pi 10a, pl lOp, ρΐ ΐθδ, and pi 10γ. Class II includes PI3K-C2a, PI3K-C2P, and PI3K-C2y. Class III includes Vps34. Class IV includes mTOR, ATM, ATR, and DNA-PK. In certain embodiments, the PI3K is a Class
I kinase. In certain embodiments, the PI3K is pi 10a, pi 10β, pi 105, or pi 10γ. In certain embodiments, the PI3K is a variant of a Class I kinase. In certain embodiments, the PI3K is a pi 10a mutant. Examples of pi 10a mutants include, but are not limited to, R38H, G106V, Kl 1 IN, K227E, N345K, C420R, P539R, E542K, E545A, E545G, E545K, Q546K, Q546P, E453Q, H710P, I800L, T1025S, M10431, M1043V, H1047L, H1047R, and H1047Y (Ikenoue et al , Cancer Res. 2005, 65, 4562-4567; Gymnopoulos et al , Proc. Natl. Acad Sci. , 2007, 104, 5569-5574). In certain embodiments, the PI3K is a Class II kinase. In certain embodiments, the PI3K is PI3K-C2a, PI3K- C2p, or PI3K-C2y. In certain embodiments, the PI3K is a Class III kinase. In certain embodiments, the PI3K is Vps34. In certain embodiments, the PI3K is a Class IV kinase. In certain embodiments, the PI3K is mTOR, ATM, ATR, or DNA-PK.
[0032] The term "PD-1" refers to programmed cell death - 1 receptor or programmed cell death protein 1, also known as cluster of differentiation 279 (CD279). The PD-1 protein in humans is encoded by the PDCD1 gene. PD-1 is a cell surface receptor that plays an important role in down-regulating the immune system and promoting self tolerance by suppressing T cell inflammatory activity. PD-1 is expressed on the surface of activated T cells and guards against autoimmunity through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (anti-inflammatory, suppressive T cells. PD-1 inhibitors activate the immune system to attack tumors and are therefore used to treat some types of cancer.
[0033] The term "PD-Ll" refers to programed death -ligand 1 also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1). PD-Ll is a protein encoded by the CD274 gene. PD-Ll is a transmembrane protein that plays a major role in suppressing the immune system. PD-Ll binds to its receptor, PD-1 (found on activated T cells, B cells, and myeloid cells) to modulate activation or inhibition of T cell responses. PD-Ll, the ligand for PD-1, is highly expressed in several cancers. Inhibition of the interaction between PD-1 and PD-Ll can enhance T-cell responses against cancer cells or tumors, and thus be useful for the treatment of cancer.
[0034] The terms "synergy," "synergism," and "synergistic" as used herein refer to a combination of therapies (e.g., use of a PI3K inhibitor of Formula (I) and a PD-1 inhibitor or PD-Ll inhibitor) that is more effective than the expected additive effects of any two or more single therapies. For example, a synergistic effect of a combination of therapies permits the use of lower dosages of one or more of the therapies and/or less frequent administration of said therapies to a subject. The ability to utilize lower dosages of therapies and/or to administer the therapies less frequently reduces the toxicity associated with the administration of the therapies to a subject without reducing the efficacy of said therapies in the prevention, management, treatment, or amelioration of a given disease, such as an autoimmune disease, inflammatory disease, or cancer including, but not limited to, chronic lymphocytic leukemia or non- Hodgkin's lymphoma. In addition, a synergistic effect can result in improved efficacy of therapies in the prevention, management, treatment, or amelioration of a given disease, such an autoimmune disease, inflammatory disease, or cancer inlcuding, but not limited to, chronic lymphocytic leukemia or non- Hodgkin's lymphoma. Finally, synergistic effects of a combination of therapies may avoid or reduce adverse or unwanted side effects associated with the use of any single therapy. The "synergy,"
"synergism," or "synergistic" effect of a combination may be determined herein by the methods of Chou et al., and/or Clarke et al. See Ting-Chao Chou, Theoretical Basis, Experimental Design, and
Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacol Rev 58:621-681 (2006), and Clarke et al., Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models, Breast Cancer Research and Treatment 46:255-278 (1997), which are both incorporated by reference for the methods of determining the "synergy," synergism," or "synergistic" effect of a combination.
[0035] The term "isotopic variant" refers to a compound that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a compound. In certain embodiments, an "isotopic variant" of a compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen ( 1 H), deuterium ( 2 H), tritium ( 3 H), carbon-11 ( 11 C), carbon-12 ( 12 C), carbon-13 ( 13 C), carbon-
14 (14C), nitrogen-13 (1 N), nitrogen-14 (14N), nitrogen-15 (15N), oxygen-14 (140), oxygen-15 (150), oxygen-16 (160), oxygen-17 (170), oxygen-18 (180), fluorine-17 (17F), fluorine-18 (18F), phosphorus-31 ( 1P), phosphorus-32 ( 2P), phosphorus-33 ( P), sulfur-32 ( 2S), sulfur-33 ( S), sulfur-34 ( 4S), sulfur-35 ( 5S), sulfur-36 ( 6S), chlorine-35 ( 5C1), chlorine-36 ( 6C1), chlorine-37 ( 7C1), bromine-79 (79Br), bromine-81 (81Br), iodine-123 (12 I), iodine-125 (125I), iodine-127 (127I), iodine-129 (129I), and iodine-131 (1 1I). In certain embodiments, an "isotopic variant" of a compound is in a stable form, that is, nonradioactive. In certain embodiments, an "isotopic variant" of a compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (¾), deuterium (2H), carbon-12 (12C), carbon-13 (1 C), nitrogen-14 (14N), nitrogen-15 (15N), oxygen-16 (160), oxygen-17 (170), oxygen-18 (180), fluorine-17 (17F), phosphorus-31 ( 1P), sulfur-32 ( 2S), sulfur-33 ( S), sulfur-34 ( 4S), sulfur-36 ( 6S), chlorine-35 ( 5C1), chlorine-37 ( 7C1), bromine-79 (79Br), bromine-81 (81Br), and iodine-127 (127I). In certain embodiments, an "isotopic variant" of a compound is in an unstable form, that is, radioactive. In certain embodiments, an "isotopic variant" of a compound contains unnatural proportions of one or more isotopes, including, but not limited to, tritium ( 3 H), carbon-11 ( 11 C), carbon-14 ( 14 C), nitrogen-13 ( 13 N), oxygen-14 (140), oxygen-15 (150), fluorine-18 (18F), phosphorus-32 ( 2P), phosphorus-33 ( P), sulfur-35 ( 5S), chlorine-36 ( 6C1), iodine-123 (12 I), iodine-125 (125I), iodine-129 (129I), and iodine-131 (1 1I). It will be understood that, in a compound as provided herein, any hydrogen can be 2H, for example, or any carbon can be 1 C, for example, or any nitrogen can be 15N, for example, or any oxygen can be 180, for example, where feasible according to the judgment of one of skill. In certain embodiments, an "isotopic variant" of a compound contains unnatural proportions of deuterium (D).
[0036] The term "alkyl" refers to a linear or branched saturated monovalent hydrocarbon radical, wherein the alkylene may optionally be substituted with one or more substituents Q as described herein. The term "alkyl" also encompasses both linear and branched alkyl, unless otherwise specified. In certain embodiments, the alkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 20 (Ci_2o), 1 to
15 (Ci-15), 1 to 10 (Ci-10), or 1 to 6 (Ci_6) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 20 (C3_2o), 3 to 15 (C3_i5), 3 to 10 (C3_i0), or 3 to 6 (C3_6) carbon atoms. As used herein, linear Ci_6 and branched C3_6 alkyl groups are also referred as "lower alkyl." Examples of alkyl groups
include, but are not limited to, methyl, ethyl, propyl (including all isomeric forms), ^-propyl, isopropyl, butyl (including all isomeric forms), «-butyl, isobutyl, sec-butyl, /-butyl, pentyl (including all isomeric forms), and hexyl (including all isomeric forms). For example, Ci_6 alkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
[0037] The term "alkylene" refers to a linear or branched saturated divalent hydrocarbon radical, wherein the alkylene may optionally be substituted with one or more substituents Q as described herein. The term "alkylene" encompasses both linear and branched alkylene, unless otherwise specified. In certain embodiments, the alkylene is a linear saturated divalent hydrocarbon radical that has 1 to 20 (Ci_2o), 1 to 15 (Ci-15), 1 to 10 (Ci-10), or 1 to 6 (Ci_6) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 20 (C3-20), 3 to 15 (C3-15), 3 to 10 (C3_i0), or 3 to 6 (C3_6) carbon atoms. As used herein, linear Ci_6 and branched C3_6 alkylene groups are also referred as "lower alkylene." Examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene (including all isomeric forms), n- propylene, isopropylene, butylene (including all isomeric forms), «-butylene, isobutylene, 7-butylene, pentylene (including all isomeric forms), and hexylene (including all isomeric forms). For example, Ci_6 alkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
[0038] The term "heteroalkylene" refers to a linear or branched saturated divalent hydrocarbon radical that contains one or more heteroatoms each independently selected from O, S, and N in the hydrocarbon chain. For example, Ci_6 heteroalkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the heteroalkylene is a linear saturated divalent hydrocarbon radical that has 1 to 20 (Ci_2o), 1 to 15 (Ci_i5), 1 to 10 (Ci_io), or 1 to 6 (Ci_6) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 20 (C3_2o), 3 to 15 (C3_i5), 3 to 10 (C3_i0), or 3 to 6 (C3_6) carbon atoms. As used herein, linear Ci_6 and branched C3_6 heteroalkylene groups are also referred as "lower heteroalkylene." Examples of heteroalkylene groups include, but are not limited to, -CH20-, -CH2OCH2-, -CH2CH20-, -CH2NH-, -CH2NHCH2- -CH2CH2NH- -CH2S- -CH2SCH2- and -CH2CH2S-. In certain embodiments, heteroalkylene may also be optionally substituted with one or more substituents Q as described herein.
[0039] The term "alkenyl" refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, four, or five, in another embodiment, one, carbon- carbon double bond(s). The alkenyl may be optionally substituted with one or more substituents Q as described herein. The term "alkenyl" also embraces radicals having "c/'s" and "trans" configurations, or alternatively, "Z" and "E" configurations, as appreciated by those of ordinary skill in the art. As used herein, the term "alkenyl" encompasses both linear and branched alkenyl, unless otherwise specified. For example, C2_6 alkenyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenyl is a linear monovalent hydrocarbon radical of 2 to 20 (C2_20), 2 to 15 (C2_i5), 2 to 10 (C2_io), or 2 to 6 (C2_6) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 20 (C3_20),
3 to 15 (C3_i5), 3 to 10 (C3_io), or 3 to 6 (C3_6) carbon atoms. Examples of alkenyl groups include, but are not limited to, ethenyl, propen-l-yl, propen-2-yl, allyl, butenyl, and 4-methylbutenyl.
[0040] The term "alkenylene" refers to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, four, or five, in another embodiment, one, carbon- carbon double bond(s). The alkenylene may be optionally substituted with one or more substituents Q as described herein. Similarly, the term "alkenylene" also embraces radicals having "cz's" and "trans" configurations, or alternatively, "E" and "Z" configurations. As used herein, the term "alkenylene" encompasses both linear and branched alkenylene, unless otherwise specified. For example, C2_6 alkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the alkenylene is a linear divalent hydrocarbon radical of 2 to 20 (C2-20), 2 to 15 (C2-15), 2 to 10 (C2-io), or 2 to 6 (C2_6) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 20 (C3_20), 3 to 15 (C3_i5), 3 to 10 (C3_i0), or 3 to 6 (C3_6) carbon atoms. Examples of alkenylene groups include, but are not limited to, ethenylene, allylene, propenylene, butenylene, and 4-methylbutenylene.
[0041] The term "heteroalkenylene" refers to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, four, or five, in another embodiment, one, carbon-carbon double bond(s), and which contains one or more heteroatoms each independently selected from O, S, and N in the hydrocarbon chain. The heteroalkenylene may be optionally substituted with one or more substituents Q as described herein. The term "heteroalkenylene" embraces radicals having a "cz's" or "tra s" configuration or a mixture thereof, or alternatively, a "Z" or "E" configuration or a mixture thereof, as appreciated by those of ordinary skill in the art. For example, C2_6 heteroalkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms. In certain embodiments, the heteroalkenylene is a linear divalent hydrocarbon radical of 2 to 20 (C2_20), 2 to 15 (C2_i5), 2 to 10 (C2_i0), or 2 to 6 (C2_6) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 20 (C3_20), 3 to 15 (C3_i5), 3 to 10 (C3_i0), or 3 to 6 (C3_6) carbon atoms. Examples of heteroalkenylene groups include, but are not limited to, -CH=CHO-, - CH=CHOCH2- -CH=CHCH20- -CH=CHS- -CH=CHSCH2- -CH=CHCH2S- or -CH=CHCH2NH-.
[0042] The term "alkynyl" refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, four, or five, in another embodiment, one, carbon- carbon triple bond(s). The alkynyl may be optionally substituted with one or more substituents Q as described herein. The term "alkynyl" also encompasses both linear and branched alkynyl, unless otherwise specified. In certain embodiments, the alkynyl is a linear monovalent hydrocarbon radical of 2 to 20 (C2_20), 2 to 15 (C2_i5), 2 to 10 (C2_i0), or 2 to 6 (C2_6) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 20 (C3_20), 3 to 15 (C3_i5), 3 to 10 (C3_i0), or 3 to 6 (C3_6) carbon atoms.
Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH) and propargyl (- CH2C≡CH). For example, C2_6 alkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
[0043] The term "cycloalkyl" refers to a cyclic saturated bridged and/or non-bridged monovalent hydrocarbon radical, which may be optionally substituted with one or more substituents Q as described herein. In certain embodiments, the cycloalkyl has from 3 to 20 (C3_2o), from 3 to 15 (C3_i5), from 3 to 10 (C3_io), or from 3 to 7 (C3_7) carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, and adamantyl.
[0044] The term "cycloalkenyl" refers to a cyclic unsaturated, nonaromatic bridged and/or non-bridged monovalent hydrocarbon radical, which may be optionally substituted with one or more substituents Q as described herein. In certain embodiments, the cycloalkenyl has from 3 to 20 (C3_2o), from 3 to 15 (C3_i5), from 3 to 10 (C3_i0), or from 3 to 7 (C3_7) carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, or cycloheptenyl,
[0045] The term "aryl" refers to a monocyclic aromatic group and/or multicyclic monovalent aromatic group that contain at least one aromatic hydrocarbon ring. In certain embodiments, the aryl has from 6 to 20 (C6_2o), from 6 to 15 (C6_i5), or from 6 to 10 (C6_i0) ring atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl. Aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl). In certain embodiments, aryl may be optionally substituted with one or more substituents Q as described herein.
[0046] The terms "aralkyl" and "arylalkyl" refer to a monovalent alkyl group substituted with one or more aryl groups. In certain embodiments, the aralkyl has from 7 to 30 (C7_30), from 7 to 20 (C7_2o), or from 7 to 16 (C7_i6) carbon atoms. Examples of aralkyl groups include, but are not limited to, benzyl, 2- phenylethyl, and 3-phenylpropyl. In certain embodiments, the aralkyl are optionally substituted with one or more substituents Q as described herein.
[0047] The term "heteroaryl" refers to a monovalent monocyclic aromatic group or monovalent polycyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms independently selected from O, S, N, and P in the ring. A heteroaryl group is bonded to the rest of a molecule through its aromatic ring. Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, one to four N atoms, and/or one or two P atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl. Examples of bicyclic heteroaryl groups include, but are not limited to, benzoiuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl,
pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, the heteroaryl may also be optionally substituted with one or more substituents Q as described herein as described herein.
[0048] The terms "heterocyclyl" and "heterocyclic" refer to a monovalent monocyclic non-aromatic ring system or monovalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from O, S, N, and P; and the remaining ring atoms are carbon atoms. In certain embodiments, the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms. A heterocyclyl group is bonded to the rest of a molecule through its non-aromatic ring. In certain embodiments, the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be spiro, fused, or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic. The heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of such heterocyclic groups include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl,
benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, β-carbolinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl,
dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl,
octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4- piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl,
tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, the heterocyclyl may also be optionally substituted with one or more substituents Q as described herein.
[0049] The terms "halogen," "halide," and "halo" refer to fluorine, chlorine, bromine, and/or iodine.
[0050] The term "optionally substituted" is intended to mean that a group or substituent, such as an alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroaryl-Ci_6 alkyl, and heterocyclyl group, may be substituted with one or more substituents Q, each of which is independently selected from, e.g., (a) oxo (=0), halo, cyano (-CN), and nitro (-N02); (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, four, or five, substituents Qa; and (c) -C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, -OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, - OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, -NRaC(0)ORd, -NRaC(0)NRbRc, -
NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, -NRaS(0)2NRbRc, -P(0)RaRd, - P(0)(ORa)Rd, -P(0)(ORa)(ORd), -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, and -S(0)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heteroaryl or heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa. As used herein, all groups that can be substituted are "optionally substituted," unless otherwise specified.
[0051] In one embodiment, each substituent Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; and (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl; and (c) -C(0)Re, -C(0)ORe, -C(0)NRfRg, -C(NRe)NRfRg, -ORe, - OC(0)Re, -OC(0)ORe, -OC(0)NRfRg, -OC(=NRe)NRfRg, -OS(0)Re, -OS(0)2Re, -OS(0)NRfRg, - OS(0)2NRfRg, -NRfRg, -NReC(0)Rh, -NReC(0)ORh, -NReC(0)NRfRg, -NReC(=NRh)NRfRg, - NReS(0)Rh, -NReS(0)2Rh, -NReS(0)NRfRg, -NReS(0)2NRfRg, -P(0)ReRh, -P(0)(ORe)Rh, - P(0)(ORe)(ORh), -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg, and -S(0)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (ii) Rf and Rg together with the N atom to which they are attached form heteroaryl or heterocyclyl.
[0052] In certain embodiments, "optically active" and "enantiomerically pure" refer to a collection of molecules, which has an enantiomeric excess of no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, no less than about 91%, no less than about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%. In certain embodiments, the compound comprises about 95% or more of the desired enantiomer and about 5% or less of the less preferred enantiomer based on the total weight of the racemate in question.
[0053] In describing an optically active compound, the prefixes R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The (+) and (-) are used to denote the optical rotation of the compound, that is, the direction in which a plane of polarized light is rotated by the optically active compound. The (-) prefix indicates that the compound is levorotatory, that is, the compound rotates the plane of polarized light to the left or counterclockwise. The (+) prefix indicates that the compound is dextrorotatory, that is, the compound rotates the plane of polarized light to the right or clockwise. However, the sign of optical rotation, (+) and (-), is not related to the absolute configuration of the molecule, R and S.
[0054] The phrase "an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof has the same meaning as the phrase "an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant of the compound referenced therein; or a pharmaceutically
acceptable salt, solvate, hydrate, or prodrug of the compound referenced therein; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant of the compound referenced therein."
[0055] The term "solvate" refers to a complex or aggregate formed by one or more molecules of a solute, e.g., a compound provided herein, and one or more molecules of a solvent, which present in a
stoichiometric or non-stoichiometric amount. Suitable solvents include, but are not limited to, water, methanol, ethanol, «-propanol, isopropanol, and acetic acid. In certain embodiments, the solvent is pharmaceutically acceptable. In one embodiment, the complex or aggregate is in a crystalline form. In another embodiment, the complex or aggregate is in a noncrystalline form. Where the solvent is water, the solvate is a hydrate. Examples of hydrates include, but are not limited to, a hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and pentahydrate.
Compounds
[0056] Disclosed herein are PI3K inhibitors of Formula (I):
Formula (I),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2-6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, - C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) d_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_ is aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -
ORla, -OC(0)Rla, -OC(0)ORla, -C(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)„-(C6_14 aryl) or -(CR5fR5g)„-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3-10 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_i0 cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, Rx, Rla, Rlb, Rlc, Rld, R5a, R5b, R5c, R5d, R5e, R5f, and R5g is optionally substituted with one or more, in one embodiment, one, two, three, four, or five, substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa; and (c) -C(0)Ra, -C(0)ORa, -C(0)NRbRc, - C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, -OC(=NRa)NRbRc, -OS(0)Ra, -
OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, -NRaC(0)ORd, -NRaC(0)NRbRc, - NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, -NRaS(0)2NRbRc, -SRa, -S(0)Ra, - S(0)2Ra, -S(0)NRbRc, and -S(0)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Qa;
wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl; and (c) -C(0)Re, -C(0)ORe, -C(0)NRfRg, -C(NRe)NRfRg, -ORe, -OC(0)Re, -OC(0)ORe, -OC(0)NRfRg, -O C(=NRe)NRfRg, -OS(0)Re, -OS(0)2Re, -OS(0)NRfRg, -OS(0)2NRfRg, -NRfRg, - NReC(0)Rh, -NReC(0)ORh, -NReC(0)NRfRg, -NReC(=NRh)NRfRg, -NReS(0)Rh, -NReS(0)2Rh, - NReS(0)NRfRg, -NReS(0)2NRfRg, -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg, and -S(0)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl; or
wherein two substituents Q that are adjacent to each other optionally form a C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa.
[0057] In one embodiment of a compound of Formula (I),
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, - C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or Ci_6 alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_ is aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -
NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)„-(C6_14 aryl) or -(CR5fR5g)„-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3-10 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, four, or five, substituents Q as defined herein.
[0058] In another embodiment of a compound of Formula (I),
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, - C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -
NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) d_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_ is aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)n-(C6_14 aryl) or -(CR5fR5g)n-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, four, or five, substituents Q as defined herein.
[0059] In yet another embodiment of a compound of Formula (I),
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2-6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, - C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene;
R5a is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)„-(C6_14 aryl) or -(CR5fR5g)„-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_i0 cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, four, or five, substituents Q as defined herein.
[0060] In still another embodiment of a compound of Formula (I),
X, Y, and Z are N;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, - C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) d_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or Ci_6 alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_ is aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, or heteroaryl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, - OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, - OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -
NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)n-(C6_14 aryl) or -(CR5fR5g)n-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_io cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3-10 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, four, or five, substituents Q as defined herein.
[0061] Synthesis of compounds of Formula (I) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0062] Also provided herein is a compound of Formula (IX):
Formula (IX),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R/a, R/b, R/c, R/d, and R/e are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_¾ alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; or (c) -C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, -OC(=NRa)NRbRc, - OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, -NRaC(0)ORd, - NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, -NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, or -S(0)2NRbRc; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa; and
R1, R2, R3, R4, R6, Rla, Rlb, Rlc, Rld, R5a, R5b, R5d, R5e, X, Y, and Z are each as defined herein.
[0063] Synthesis of compounds of Formula (IX) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0064] In one embodiment, the compound of Formula (IX) has the structure of Formula (IXa):
Formula (IXa),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5d, R5e, R7a, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0065] Synthesis of compounds of Formula (IXa) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0066] In another embodiment, of Formula (IXb):
Formula (IXb),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5d, R5e, R7a, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0067] Synthesis of compounds of Formula (IXb) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0068] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb), one of R7a, R7b, R7c, R7d, and R7e is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is C6_i4 aryl, e.g., phenyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is heteroaryl, e.g., 5-membered or 6-membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R7b, R7c, R7d, and R7e is heterocyclyl, e.g., 5-membered or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R¾, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R¾, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is phenyl, 2- fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3- chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, imidazol-l -yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, l -methylpiperidin-4-yl, or 4-methylpiperazin- 1-yl; and in certain embodiments, one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl - pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2- methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l -methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, l-ethylpiperidin-4-yl, 1 - isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l -yl.
[0069] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb), R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is C6_i4 aryl, e.g., phenyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is heteroaryl, e.g., 5-membered or 6- membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is heterocyclyl, e.g., 5-membered or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-
methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3- yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, 1- methylpiperidin-4-yl, or 4-methylpiperazin-l-yl; and in certain embodiments, R7a is phenyl, 2- fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2- methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4- chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2- fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin- 1 -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, 1- ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin- 1 -yl .
[0070] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb),
R1 is hydrogen or -ORla, where Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently hydrogen, halo, Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5d and R5e are each independently Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R7a is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are N; where Rx is a hydrogen or Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa.
[0071] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one or more halo;
R5a and R5b are hydrogen;
R5d and R5e are each independently Ci_6 alkyl;
R7a is C6-14 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R7", R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0072] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is Cc-14 aryl, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionalh7 substituted with one, two, three, or four substituents Qa;
R7", R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0073] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0074] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb).
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X. Y. and Z are each independently N or CH.
[0075] In certain embodiments of compounds of Formulae (IX), (IXa), or (IXb).
R1 is hydrogen or methoxy;
R2 is hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0076] Also provided herein is a compound of Formula (X):
Formula (X),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5d, R5e, R7a, R7b, R7c, R7d, and R7e are each as defined herein.
[0077] Synthesis of compounds of Formula (X) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0078] In one embodiment, the compound of Formula (X) has the structure of Formula (Xa):
Formula (Xa),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5d, R5e, R7a, R7b, R7c, R7d, and R7e are each as defined herein.
[0079] Synthesis of compounds of Formula (Xa) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0080] In another embodiment, the compound of Formula (X) has the structure of Formula (Xb):
Formula (Xb),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5d, R5e, R7a, R7b, R7c, R7d, and R7e are each as defined herein.
[0081] Synthesis of compounds of Formula (Xb) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0082] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb), one of R7a, R7b, R7c, R7d, and R7e is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is C6_i4 aryl, e.g., phenyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is heteroaryl, e.g., 5-membered or 6-membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R7b, R7c, R7d, and R7e is heterocyclyl, e.g., 5-membered or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R¾, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R¾, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is phenyl, 2- fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3- chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, imidazol-l -yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, l -methylpiperidin-4-yl, or 4-methylpiperazin- 1-yl; and in certain embodiments, one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3-moφholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl - pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2- methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l -methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, l-ethylpiperidin-4-yl, 1 - isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l -yl.
[0083] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb), R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is C6_i4 aryl, e.g., phenyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is heteroaryl, e.g., 5-membered or 6-membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is heterocyclyl, e.g., 5-membered or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3- yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, 1- methylpiperidin-4-yl, or 4-methylpiperazin-l-yl; and in certain embodiments, R7a is phenyl, 2- fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2- methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4- chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-mo holin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2- fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin- 1 -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, 1- ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin- 1 -yl .
[0084] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb),
R1 is hydrogen or -ORla, where Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently hydrogen, halo, Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5d and R5e are each independently Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R7a is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0085] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci_6 alkyl, optionally substituted with one or more halo;
R5a and R5b are hydrogen;
R5d and R5e are each independently Ci_6 alkyl;
R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d. and R7e are hydrogen.
[0086] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is C6_i4 aryl, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R7", R7c, R7d. and R7e are hydrogen.
[0087] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Q ; and
R7", R7c. R7d, and R7e are hydrogen.
[0088] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl. piperidinyl, or
piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R b, R c, R d, and R e are hydrogen.
[0089] In certain embodiments of compounds of Formulae (X), (Xa), or (Xb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are hydrogen;
R5d and R5e are methyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0090] Also provided herein is a compound of Formula (XI):
Formula (XI),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R/a, R/b, R/c, R/d, and R/e are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; or (c) -C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, -OC(=NRa)NRbRc, - OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, -NRaC(0)ORd, - NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, -NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, or -S(0)2NRbRc; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa; and
R1, R2, R3, R4, R6, Rla, Rlb, Rlc, Rld, R5a, R5b, R5f, R5g, X, Y, and Z are each as defined herein.
[0091] Synthesis of compounds of Formula (XI) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0092] In one embodiment, the compound of Formula (XI) has the structure of Formula (XIa):
Formula (XIa),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5f, R5g, R7a, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0093] Synthesis of compounds of Formula (XIa) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0094] In another embodiment, of Formula (Xlb):
Formula (Xlb),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R5f, R5g, R7a, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0095] Synthesis of compounds of Formula (Xlb) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0096] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb), R5a and R5b are each independently (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc; and R1, R2, R3, R4, R5f, R5g, R6, R7a, R7b, R7c, R7d, R7e, X, Y, Z, Rla, Rlb, Rlc, and Rld are defined herein elsewhere.
[0097] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb), one of R7a, R7", R7c, R7d, and R7e is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is C6_i4 aryl, e.g., phenyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of
R7a, R7^ R7c, R7d, and R7e is heteroaryl, e.g., 5-membered or 6-membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R7b, R7c, R7d, and R7e is heterocyclyl, e.g., 5-membered or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R¾, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R¾, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, one of R7a, R^, R7c, R7d, and R7e is phenyl, 2- fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3- chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, imidazol-l -yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, l -methylpiperidin-4-yl, or 4-methylpiperazin- 1-yl; and in certain embodiments, one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3-moφholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl - pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2- methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l -methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, l-ethylpiperidin-4-yl, 1 - isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l -yl.
[0098] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb), R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is C6_i4 aryl, e.g., phenyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is heteroaryl, e.g., 5-membered or 6- membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is heterocyclyl, e.g., 5-membered or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; in certain embodiments, R7a is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, imidazol-l -yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3- yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, 1 - methylpiperidin-4-yl, or 4-methylpiperazin-l-yl; and in certain embodiments, R7a is phenyl, 2- fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2- methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-
chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3- methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-mo holin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2- fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin- 1 -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, 1- ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin- 1 -yl .
[0099] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb),
R1 is hydrogen or -ORla, where Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5f and R5g are each independently hydrogen, halo, Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q; or R5f and R5g together with the carbon atom to which they are attached form Ci_i0 cycloalkyl or heterocyclyl, each of which is optionally substituted with one, two, three, four, or five substituents Q;
R7a is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are N; where Rx is a hydrogen or Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa.
[0100] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one or more halo;
R5a and R5b are each independently Ci_6 alkyl;
R5f and R5g are each independently hydrog en or Ci_6 alkyl; or R5f and R5g together with the carbon atom to which they are attached form CMO cycloalkyl;
R7a is C6-14 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0101] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R5f and R5g are hydrogen; or R5f and R5g together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R7a is Οή-ΐ4 aryl, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0102] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R5f and R5g are hydrogen; or R5f and R5g together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0103] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R5f and R5g are hydrogen; or R5f and R5g together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0104] In certain embodiments of compounds of Formulae (XI), (XIa), or (Xlb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R5f and R5g are hydrogen; or R5f and R5g together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0105] Also provided herein is a compound of Formula (XVI):
Formula (XVI),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R7a, R7b, R7c, R7d, and R7e are each as defined herein.
[0106] Synthesis of compounds of Formula (XVI) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0107] In one embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is C6-i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0108] In another embodiment of a compound of Formula (XVI), one of R7a, R7b, R7c, R7d, and R7e is C6_14 aryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6,
R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0109] In yet another embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4,
R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0110] In yet another embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is
5-membered or 6-membered heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0111] In yet another embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0112] In yet another embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is 5-membered or 6-membered heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0113] In yet another embodiment of a compound of Formula (XVI), one of R7a, R^, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0114] In yet another embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0115] In yet another embodiment of a compound of Formula (XVI), one of R7a, R^, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3- dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1 - methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l -isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1 - methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0116] In still another embodiment of a compound of Formula (XVI), one of R7a, R7", R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4- methoxyphenyl, imidazol-l -yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, l-methylpiperidin-4-yl, or 4- methylpiperazin-l -yl; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0117] In one embodiment of a compound of Formula (XVI), R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0118] In another embodiment of a compound of Formula (XVI), R7a is C6_i4 aryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0119] In yet another embodiment of a compound of Formula (XVI), R7a is heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0120] In yet another embodiment of a compound of Formula (XVI), R7a is 5-membered or 6-membered heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0121] In yet another embodiment of a compound of Formula (XVI), R7a is heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0122] In yet another embodiment of a compound of Formula (XVI), R7a is 5-membered or 6-membered heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0123] In yet another embodiment of a compound of Formula (XVI), R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0124] In yet another embodiment of a compound of Formula (XVI), R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0125] In yet another embodiment of a compound of Formula (XVI), R7a is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl - pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2- methylpyridin-4-yl, 2-(4-methylpiperazin-l-yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, l-ethylpiperidin-4-yl, 1- isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0126] In yet another embodiment of a compound of Formula (XVI), R7a is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2- methylpyridin-4-yl, 2-methoxypyridin-4-yl, l-methylpiperidin-4-yl, or 4-methylpiperazin-l-yl; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0127] In one embodiment of a compound of Formula (XVI),
R1 is hydrogen or -ORla, where Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R7a is C6-i4 aryl, heteroaiyl, or heterocyclyl, each of which is optionally substituted w ith one, two, three, or four substituents Qa; and
R713, R7c, R7d, and R7e are hydrogen.
[0128] In one embodiment of a compound of Formula (XVI),
R1 is hydrogen or methoxy:
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one or more halo;
R5a and R5b are each independently Ci_6 alkyl;
R7a is C6-i4 aryl, heteroaiyl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0129] In one embodiment of a compound of Formula (XVI),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R7a is C6_i4 aryl, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0130] In one embodiment of a compound of Formula (XVI),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0131] In one embodiment of a compound of Formula (XVI),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R1 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, four, or five substituents Q; and
R b, R c, R d, and R e are hydrogen.
In one embodiment of a compound of Formula (XVI),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are methyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R b, R c, R d, and R e are hydrogen.
[0133] In one embodiment, the compound of Formula (XVI) has the structure of Formula (XVIa):
Formula (XVIa),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R7a, R¾, R7c, R7d, and R7e are each as defined herein.
[0134] Synthesis of compounds of Formula (XVIa) is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
[0135] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0136] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is C6_i4 aryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0137] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0138] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is 5- membered or 6-membered heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0139] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0140] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is 5- membered or 6-membered heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0141] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0142] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0143] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3- dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l-yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1- methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1- methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0144] In one embodiment of a compound of Formula (XVIa), one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4- methoxyphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, l-methylpiperidin-4-yl, or 4- methylpiperazin-l-yl; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0145] In one embodiment of a compound of Formula (XVIa), R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0146] In one embodiment of a compound of Formula (XVIa), R7a is C6_i4 aryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0147] In one embodiment of a compound of Formula (XVIa), R7a is heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0148] In one embodiment of a compound of Formula (XVIa), R7a is 5-membered or 6-membered heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0149] In one embodiment of a compound of Formula (XVIa), R7a is heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0150] In one embodiment of a compound of Formula (XVIa), R7a is 5-membered or 6-membered heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0151] In one embodiment of a compound of Formula (XVIa), R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0152] In one embodiment of a compound of Formula (XVIa), R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0153] In one embodiment of a compound of Formula (XVIa), R7a is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3-moφholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl - pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2- methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l -methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, l-ethylpiperidin-4-yl, 1 - isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l -yl.
[0154] In one embodiment of a compound of Formula (XVIa), R7a is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, imidazol-l -yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-
methylpyridin-4-yl, 2-methoxypyridin-4-yl, l-methylpiperidin-4-yl, or 4-methylpiperazin-l-yl; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0155] In one embodiment of a compound of Formula (XVIa),
R1 is hydrogen or -ORla, where Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently hydrogen or Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R7a is Οή-ΐ4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0156] In one embodiment of a compound of Formula (XVIa),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci_6 alkyl, optionally substituted with one or more halo;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0157] In one embodiment of a compound of Formula (XVIa),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is Οή-ΐ4 aryl, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0158] In one embodiment of a compound of Formula (XVIa),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is
optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
In one embodiment of a compound of Formula (XVIa),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrrolidinyl, piperidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R b, R c, R d, and R e are hydrogen.
In one embodiment of a compound of Formula (XVIa),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R b, R c, R d, and R e are hydrogen.
[0161] In another embodiment of Formula (XVIb):
Formula (XVIb),
or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein R1, R2, R3, R4, R6, R5a, R5b, R7a, R¾, R7c, R7d, and R7e are each as defined herein.
[0162] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is C6_14 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0163] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is C6-i4 aryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0164] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0165] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is 5- membered or 6-membered heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0166] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0167] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is 5- membered or 6-membered heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0168] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0169] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R7b, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0170] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3- dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l-yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1- methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1- methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0171] In one embodiment of a compound of Formula (XVIb), one of R7a, R7b, R7c, R7d, and R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4- methoxyphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 2-methoxypyridin-4-yl, l-methylpiperidin-4-yl, or 4-
methylpiperazin-l -yl; and R1, R2, R3, R4, R6, R5a, R5b, the remaining of R7a, R¾, R7c, R7d, and R7e, X, Y, and Z are each as defined herein.
[0172] In one embodiment of a compound of Formula (XVIb), R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, four, or five substituents Q; and R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0173] In one embodiment of a compound of Formula (XVIb), R7a is C6_i4 aryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0174] In one embodiment of a compound of Formula (XVIb), R7a is heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0175] In one embodiment of a compound of Formula (XVIb), R7a is 5-membered or 6-membered heteroaryl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0176] In one embodiment of a compound of Formula (XVIb), R7a is heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R7", R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0177] In one embodiment of a compound of Formula (XVIb), R7a is 5-membered or
6-membered heterocyclyl, which is optionally substituted with one, two, three, or four substituents Qa; and
R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0178] In one embodiment of a compound of Formula (XVIb), R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents
Qa; and R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0179] In one embodiment of a compound of Formula (XVIb), R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa; and R1, R2, R3, R4, R6, R5a, R5b, R¾, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0180] In one embodiment of a compound of Formula (XVIb), R7a is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-(3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4- bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 3-moφholin-4-ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl - pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2- methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin-4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l -methylpyrrolidin-3-yl, piperidin-4-yl, l-methylpiperidin-4-yl, l-ethylpiperidin-4-yl, 1 - isopropylpiperidin-4-yl, l-acetylpiperidin-4-yl, l-methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l -yl.
[0181] In one embodiment of a compound of Formula (XVIb), R7a is phenyl, 2-fluorophenyl, 2- chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-
methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl. 4-bromophenyl, 4-methoxyphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2- methylpyridin-4-yl, 2-methoxypyridin-4-yl, l-methylpiperidin-4-yl, or 4-methylpiperazin-l-yl; and R1, R2, R3, R4, R6, R5a, R5 , R7b, R7c, R7d, R7e, X, Y, and Z are each as defined herein.
[0182] In one embodiment of a compound of Formula (XVIb),
R1 is hydrogen or -ORla, where Rla is alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently hydrogen or Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one. two. three, or four substituents Qa; and
R¾, R7c, R7d. and R7e are hydrogen.
[0183] In one embodiment of a compound of Formula (XVIb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R and R4 are hydrogen;
Rb is CM, alkyl, optionally substituted with one or more halo;
R5a and R5b are each independently hydrog en or alkyl;
R7a is C6_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0184] In one embodiment of a compound of Formula (XVIb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a
IS Οό-14 3.Γ\ 1, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R7". R7c, R7d, and R7e are hydrogen.
[0185] In one embodiment of a compound of Formula (XVIb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0186] In one embodiment of a compound of Formula (XVIb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0187] In one embodiment of a compound of Formula (XVIb),
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa; and
R¾, R7c, R7d, and R7e are hydrogen.
[0188] In one embodiment of compounds of Formulae (XVI), (XVIa), or (XVIb), R5a and R5b are each independently (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, - OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc; and R1, R2, R3, R4, R6, R7a, R7b, R7c, R7d, R7e, Rla, Rlb, Rlc, and Rld are defined herein elsewhere.
[0189] In one embodiment of a compound of any of the formulae provided herein,
R1 is hydrogen or -ORla, where Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one, two, three, four, or five substituents Q;
R5a and R5b are each independently hydrogen or Ci_6 alkyl optionally substituted with one, two, three, four, or five substituents Q;
R7a is C¾_i4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are N; where Rx is a hydrogen or Ci_6 alkyl, optionally substituted with one, two, three, or four substituents
Qa.
[0190] In one embodiment of a compound of any of the formulae provided herein,
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is Ci-6 alkyl, optionally substituted with one or more halo;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is Οή-ΐ4 aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0191] In one embodiment of a compound of any of the formulae provided herein,
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is C¾_i4 aryl, monocyclic heteroaryl, or monocyclic heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0192] In one embodiment of a compound of any of the formulae provided herein,
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, 5- or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0193] In one embodiment of a compound of any of the formulae provided herein,
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0194] In one embodiment of a compound of any of the formulae provided herein,
R1 is hydrogen or methoxy;
R2 is hydrogen;
R3 and R4 are hydrogen;
R6 is difluoromethyl;
R5a and R5b are each independently hydrogen or Ci_6 alkyl;
R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one, two, three, or four substituents Qa;
R¾, R7c, R7d, and R7e are hydrogen; and
X, Y, and Z are each independently N or CH.
[0195] The groups or variables, R1, R2, R3, R4, R6, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R7a, R7b, R7c, R7d, R7e, m, n, X, Y, and Z in any of the Formulae provided herein, e.g., Formulae (I), (IX), (X), (XI), (XVI), (IXa), (Xa), (XIa), (XVIa), (IXb), (Xb), (Xlb), (XVIb), are further defined in the embodiments described herein. All combinations of the embodiments provided herein for such groups and/or variables are within the scope of this disclosure.
[0196] In certain embodiments, R1 is hydrogen. In certain embodiments, R1 is cyano. In certain embodiments, R1 is halo. In certain embodiments, R1 is fluoro, chloro, bromo, or iodo. In certain embodiments, R1 is nitro. In certain embodiments, R1 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is C2-e alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is C2-e alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is C6_i4 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R is C7-15 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0197] In certain embodiments, R1 is -C(0)Rla, wherein Rla is as defined herein. In certain embodiments, R1 is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R1 is -C(0)NRlbRlc, wherein
Rlb and Rlc are each as defined herein. In certain embodiments, R1 is -C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R1 is -ORla, wherein Rla is as defined herein. In certain embodiments, R1 is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R1 is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R1 is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R1 is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R1 is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R1 is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R1 is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R1 is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R1 is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R1 is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R1 is -NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R1 is -NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R1 is -NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R1 is -NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R1 is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R1 is -NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R1 is -NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R1 is -NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R1 is -SRla, wherein Rla is as defined herein. In certain embodiments, R1 is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R1 is -S(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R1 is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R1 is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0198] In certain embodiments, R2 is hydrogen. In certain embodiments, R2 is cyano. In certain embodiments, R2 is halo. In certain embodiments, R2 is fluoro, chloro, bromo, or iodo. In certain embodiments, R2 is nitro. In certain embodiments, R2 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is C2_6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is C3_7 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is C6_i4 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is C7_i5 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R2 is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments,
R2 is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0199] In certain embodiments, R2 is -C(0)Rla, wherein Rla is as defined herein. In certain embodiments, R2 is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R2 is -C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R2 is -C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R2 is -ORla, wherein Rla is as defined herein. In certain embodiments, R1 is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R1 is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R2 is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R2 is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R2 is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R2 is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R2 is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R2 is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R2 is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R2 is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R2 is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R2 is amino (-NH2). In certain embodiments, R2 is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R2 is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R2 is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R2 is - NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R2 is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R2 is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R2 is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R2 is - SRla, wherein Rla is as defined herein. In certain embodiments, R2 is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R2 is -S(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R2 is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R is - S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0200] In certain embodiments, R3 is hydrogen. In certain embodiments, R3 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R3 is hydrogen, methyl, ethyl, or propyl (e.g., n-propyl, isopropyl, or 2-isopropyl).
[0201] In certain embodiments, R4 is hydrogen. In certain embodiments, R4 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R4 is hydrogen, methyl, ethyl, or propyl (e.g., n-propyl, isopropyl, or 2-isopropyl).
[0202] In certain embodiments, R3 and R4 are linked together to form a bond. In certain embodiments, R3 and R4 are linked together to form Ci_6 alkylene, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R3 and R4 are linked together to form
methylene, ethylene, or propylene, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R3 and R4 are linked together to form Ci_6 heteroalkylene, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R3 and R4 are linked together to form C2_6 alkenylene, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R3 and R4 are linked together to form C2_6 heteroalkenylene, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0203] In certain embodiments, R6 is hydrogen. In certain embodiments, R6 is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R6 is Ci-6 alkyl, optionally substituted with one or more, in one embodiment, one, two, or three, halo. In certain embodiments, R6 is Ci_6 alkyl, optionally substituted with one or more, in one embodiment, one, two, or three, fluoro. In certain embodiments, R6 is methyl, fluoromethyl, difluoromethyl, or
trifluoromethyl. In certain embodiments, R6 is difluoromethyl. In certain embodiments, R6 is -S-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R6 is -S(0)-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R6 is -S02-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0204] In certain embodiments, R5a is hydrogen. In certain embodiments, R5a is not hydrogen. In certain embodiments, R5a is halo. In certain embodiments, R5a is fluoro, chloro, bromo, or iodo. In certain embodiments, R5a is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is methyl, ethyl, propyl, or butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain embodiments, R5a is methyl. In certain embodiments, R5a is C2-6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is C3_7 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is C6_i4 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is C7_i5 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0205] In certain embodiments, R5a is -C(0)Rla, wherein Rla is as defined herein. In certain
embodiments, R5a is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5a is - C(0)ORla, wherein Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents
Q as described herein. In certain embodiments, R5a is -C(0)OCH3. In certain embodiments, R5a is - C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5a is - C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5a is - ORla, wherein Rla is as defined herein. In certain embodiments, R5a is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5a is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5a is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5a is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5a is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5a is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R5a is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5a is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5a is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5a is amino (-NH2). In certain embodiments, R5a is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5a is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5a is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5a is - NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R5a is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5a is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5a is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5a is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5a is - SRla, wherein Rla is as defined herein. In certain embodiments, R5a is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5a is -S(0)2Rla, wherein Rla is as defined herein. In certain
embodiments, R5a is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain
embodiments, R5a is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0206] In certain embodiments, R5a is (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, or heteroaryl, each of which is optionally substituted with one, two, three, four, or five substituents Q; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc. In certain embodiments, R5a is (a) hydrogen or halo; or (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, or heteroaryl, each of which is optionally substituted with one, two, three, four, or five substituents Q.
[0207] In certain embodiments, R5b is halo. In certain embodiments, R5b is fluoro, chloro, bromo, or iodo. In certain embodiments, R5b is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is methyl, ethyl, propyl, or butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain
embodiments, R5b is methyl. In certain embodiments, R5b is C2_6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is C3_7 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is C6_i4 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments,
R5b is C7-15 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is not heterocyclyl.
[0208] In certain embodiments, R5b is -C(0)Rla, wherein Rla is as defined herein. In certain
embodiments, R5b is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5b is - C(0)ORla, wherein Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is -C(0)OCH3. In certain embodiments, R5b is - C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5b is - C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5b is - ORla, wherein Rla is as defined herein. In certain embodiments, R5b is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5b is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5b is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5b is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5b is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5b is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R5b is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5b is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5b is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5b is amino (-NH2). In certain embodiments, R5b is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5b is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5b is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5b is - NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R5b is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5b is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5b is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5b is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5b is - SRla, wherein Rla is as defined herein. In certain embodiments, R5b is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5b is -S(0)2Rla, wherein Rla is as defined herein. In certain
embodiments, R5b is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5b is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0209] In certain embodiments, R5a and R5b are each independently methyl, ethyl, ^-propyl, isopropyl, n- butyl, isobutyl, or /-butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5a and R5b are each independently methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl, each optionally substituted with one or more halo. In certain embodiments, R5a and R5b are each independently methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain embodiments, R5a and R5b are each methyl.
[0210] In certain embodiments, R5c is C6_i aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5b is C6_i aryl substituted at the 2-position with one substituent Q as described herein. In certain embodiments, R5c is phenyl or naphthyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5c is phenyl, naphtha- 1 -yl, or naphtha-2-yl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5c is phenyl, 4- chlorophenyl, 4-methoxyphenyl, or naphtha-2-yl. In certain embodiments, R5c is heteroaryl, optionally substituted with one or more substituents as described herein. In certain embodiments, R5c is monocyclic heteroaryl, optionally substituted with one or more substituents as described herein. In certain embodiments, R5c is 5- or 6-membered heteroaryl, optionally substituted with one or more substituents as described herein. In certain embodiments, R5c is bicyclic heteroaryl, optionally substituted with one or more substituents as described herein.
[0211] In certain embodiments, R5c is -(CR5fR5g)n-(C6_i4 aryl), wherein the C6.u aryl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5c is benzyl, 2-phenethyl, 3-phenylpropyl, or 4-phenylbutyl, wherein each of the phenyl moiety is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5c is benzyl, 2-phenethyl, 3-phenylpropyl, or 4-phenylbutyl. In certain embodiments, R5c is benzyl, fluorobenzyl, chlorobenzyl, bromobenzyl, cyanobenzyl, methylbenzyl, or methoxybenzyl. In certain embodiments, R5c is (naphthalen- l -yl)methyl, (naphthalen-2-yl)methyl 2-(naphthalen-l-yl)ethyl, 2-(naphthalen-2-yl)ethyl, 3 -(naphthalen- 1 -yl)propyl, 3 -(naphthalen-2-yl)propyl, 4-(naphthalen- 1 -yl)butyl, or 4-(naphthalen-2-yl)butyl, wherein each of the naphthyl moiety is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, n is 0 or 1. In one embodiment, n is 1. In one embodiment, n is 1, 2, 3, or 4. In certain embodiments, R5c is -CH2-(C6_i aryl), wherein the C6_i aryl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5c is -C(CH3)2-(C6_i aryl), wherein the C6_i aryl is optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5c is -CH2-phenyl or -CH2-naphthyl, wherein the phenyl or naphthyl is each optionally substituted with one, two, three, four, or five substituents Q as described herein, such as, e.g., optionally substituted with one or more F, CI, Br, I, -CN, -CH3, -CF3, -OCH3, or -OCF3. In certain embodiments, R5c is -CH2- phenyl, -CH2-naphtha-l -yl, or -CH2-naphtha-2-yl, wherein the phenyl or naphthyl is each optionally
substituted with one, two, three, four, or five substituents Q as described herein, such as, e.g., optionally substituted with one or more F, CI, Br, I, -CN, -CH3, -CF3, -OCH3, or -OCF3. In certain embodiments, R5c is -CH2-phenyl, -CH2-naphtha-l-yl, or -CH2-naphtha-2-yl, wherein the phenyl or naphthyl is each optionally substituted with one or more F, CI, Br, I, -CN, -CH3, -CF3, -OCH3, -OCF3. In other embodiments, R5c is -CH2-phenyl, -CH2-naphtha-l-yl, or -CH2-naphtha-2-yl, wherein the phenyl or naphthyl is each optionally substituted with one or more F, CI, Br, I, -CN, -CH3, -CF3, -OCH3, -OCF3, - 0-(d_4 alkylene)-N-(C1_4 alkyl)2 (e.g., -0-CH2CH2-N(CH3)2), -O-heterocyclyl (e.g., -0-(N- methylpiperidinyl) or -O-piperidinyl), -O-heteroaryl (e.g., -O-pyridyl), -NH-heterocyclyl (e.g., -NH- (N-methylpiperidinyl), -NH-(N-methylpyrrolidinyl), -NH-piperidinyl, or -NH-pyrrolidinyl), -NH- heteroaryl (e.g., -NH-pyridyl), -NCH3-heterocyclyl (e.g., -NCH3-(N-methylpiperidinyl), -NCH3-(N- methylpyrrolidinyl), -NCH3-piperidinyl, or -NCH3-pyrrolidinyl), -NCH3-heteroaryl (e.g., -NCH3- pyridyl), heterocyclyl (e.g., piperidinyl, piperazinyl, N-methylpiperidinyl, or N-methylpiperazinyl), or heteroaryl (e.g., pyridyl or imidazolyl). In certain embodiments, R5c is -CH2-phenyl, -C(CH3)2-phenyl, - CH2-(2-methylphenyl), -CH2-(2-methoxylphenyl), -CH2-(2 -fluorophenyl), -CH2-(2-chlorophenyl), - CH2-(2-bromophenyl), -CH2-(3-methylphenyl), -CH2-(3-methoxylphenyl), -CH2-(3 -fluorophenyl), - CH2-(3-chlorophenyl), -CH2-(3-bromophenyl), -CH2-(4-methylphenyl), -CH2-(4-methoxylphenyl), - CH2-(4-fluorophenyl), -CH2-(4-chlorophenyl), -CH2-(4-bromophenyl), -CH2-naphtha-l-yl, or -CH2- naphtha-2-yl.
[0212] In certain embodiments, R5c is -(CR5fR5g)-(C6_i4 aryl), wherein the C6_i4 aryl is optionally substituted with one, two, three, four, or five substituents Q as described herein, and wherein R5f and R5g together with the carbon atom to which they are attached form a 3 - to 6-membered cycloalkyl or heterocyclyl. In one embodiment, R5c is -cyclopropyl -phenyl. In one embodiment, R5c is -cyclobutyl- phenyl. In one embodiment, R5c is -cyclopentyl -phenyl. In one embodiment, R5c is -cyclohexyl -phenyl.
[0213] In certain embodiments, R5c is -(CR5fR5g)n-heteroaryl, wherein the heteroaryl is optionally substituted with one, two, three, four, or five substituents Q as described herein, wherein n is defined herein elsewhere. In certain embodiments, R5c is -CH2-(monocyclic heteroaryl), wherein the heteroaryl is optionally substituted with one or more substituents as described herein. In certain embodiments, R5c is - CH2-(5- or 6-membered heteroaryl), wherein the heteroaryl is optionally substituted with one or more substituents as described herein. In certain embodiments, R5c is -CH2-(bicyclic heteroaryl), wherein the heteroaryl is optionally substituted with one or more substituents as described herein.
[0214] In certain embodiments, R5d is hydrogen. In certain embodiments, R5d is halo. In certain embodiments, R5d is fluoro, chloro, bromo, or iodo. In certain embodiments, R5d is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is methyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is methyl. In certain embodiments, R5d is methyl, ethyl, propyl, or butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain embodiments, R5d is C2_6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q
as described herein. In certain embodiments, R5d is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is C6.u aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is C7_i5 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0215] In certain embodiments, R5d is -C(0)Rla, wherein Rla is as defined herein. In certain
embodiments, R5d is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5d is - C(0)ORla, wherein Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5d is -C(0)OCH3. In certain embodiments, R5d is - C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5d is - C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5d is - ORla, wherein Rla is as defined herein. In certain embodiments, R5d is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5d is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5d is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5d is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5d is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5d is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R5d is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5d is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5d is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5d is amino (-NH2). In certain embodiments, R5d is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5d is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5d is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5d is - NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R5d is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5d is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5d is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5d is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5d is - SRla, wherein Rla is as defined herein. In certain embodiments, R5d is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5d is -S(0)2Rla, wherein Rla is as defined herein. In certain
embodiments, R5d is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5d is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0216] In certain embodiments, R5e is hydrogen. In certain embodiments, R5e is halo. In certain embodiments, R5e is fluoro, chloro, bromo, or iodo. In certain embodiments, R5e is Ci_6 alkyl, optionally
substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is methyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is methyl. In certain embodiments, R5e is methyl, ethyl, propyl, or butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain embodiments, R5e is C2_6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is C6_i4 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is C7_i5 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0217] In certain embodiments, R5e is -C(0)Rla, wherein Rla is as defined herein. In certain
embodiments, R5e is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5e is - C(0)ORla, wherein Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5e is -C(0)OCH3. In certain embodiments, R5e is - C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5e is - C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5e is - ORla, wherein Rla is as defined herein. In certain embodiments, R5e is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5e is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5e is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5e is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5e is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5e is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R5e is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5e is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5e is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5e is amino (-NH2). In certain embodiments, R5e is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5e is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5e is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5e is - NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R5e is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5e is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5e is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5e is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5e is -
SRla, wherein Rla is as defined herein. In certain embodiments, R5e is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5e is -S(0)2Rla, wherein Rla is as defined herein. In certain
embodiments, R5e is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain
embodiments, R5e is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0218] In certain embodiments, R5f is hydrogen. In certain embodiments, R5f is halo. In certain embodiments, R5f is fluoro, chloro, bromo, or iodo. In certain embodiments, R5f is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is methyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is methyl. In certain embodiments, R5f is methyl, ethyl, propyl, or butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain
embodiments, R5f is C2_6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments,
R5f
is Cg-14 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is C7_i5 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0219] In certain embodiments, R5f is -C(0)Rla, wherein Rla is as defined herein. In certain
embodiments, R5f is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5f is - C(0)ORla, wherein Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5f is -C(0)OCH3. In certain embodiments, R5f is - C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5f is - C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5f is - ORla, wherein Rla is as defined herein. In certain embodiments, R5f is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5f is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5f is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5f is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5f is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5f is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R5f is -OS(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5f is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5f is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5f is amino (-NH2). In certain embodiments, R5f is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5f is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5f is -
NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R5f is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5f is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5f is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5f is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5f is - SRla, wherein Rla is as defined herein. In certain embodiments, R5f is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5f is -S(0)2Rla, wherein Rla is as defined herein. In certain
embodiments, R5f is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5f is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0220] In certain embodiments, R5g is hydrogen. In certain embodiments, R5g is halo. In certain embodiments, R5g is fluoro, chloro, bromo, or iodo. In certain embodiments, R5g is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is methyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is methyl. In certain embodiments, R5g is methyl, ethyl, propyl, or butyl, each optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, or /-butyl. In certain embodiments, R5g is C2_6 alkenyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is C2_6 alkynyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is C3_i0 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is C6_i4 aryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is C7_i5 aralkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is heteroaryl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0221] In certain embodiments, R5g is -C(0)Rla, wherein Rla is as defined herein. In certain
embodiments, R5g is -C(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5g is - C(0)ORla, wherein Rla is Ci_6 alkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, R5g is -C(0)OCH3. In certain embodiments, R5g is - C(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5g is - C(NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5g is - ORla, wherein Rla is as defined herein. In certain embodiments, R5g is -OC(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5g is -OC(0)ORla, wherein Rla is as defined herein. In certain embodiments, R5g is -OC(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5g is -OC(=NRla)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5g is -OS(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5g is - OS(0)2Rla, wherein Rla is as defined herein. In certain embodiments, R5g is -OS(0)NRlbRlc, wherein Rlb
and Rlc are each as defined herein. In certain embodiments, R5g is -OS(0)2NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5g is -NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain embodiments, R5g is amino (-NH2). In certain embodiments, R5g is - NRlaC(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5g is - NRlaC(0)ORld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5g is - NRlaC(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5g is - NRlaC(=NRld)NRlbRlc, wherein Rla, Rlb, Rlc, and Rld are each as defined herein. In certain embodiments, R5g is -NRlaS(0)Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5g is - NRlaS(0)2Rld, wherein Rla and Rld are each as defined herein. In certain embodiments, R5g is - NRlaS(0)NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5g is - NRlaS(0)2NRlbRlc, wherein Rla, Rlb, and Rlc are each as defined herein. In certain embodiments, R5g is - SRla, wherein Rla is as defined herein. In certain embodiments, R5g is -S(0)Rla, wherein Rla is as defined herein. In certain embodiments, R5g is -S(0)2Rla, wherein Rla is as defined herein. In certain
embodiments, R5g is -S(0)NRlbRlc, wherein Rlb and Rlc are each as defined herein. In certain
embodiments, R5g is -S(0)2NRlbRlc; wherein Rlb and Rlc are each as defined herein.
[0222] In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_7 cycloalkyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a cyclopropyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a cyclobutyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a cyclopentyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a cyclohexyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a cycloheptyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a cyclopropyl.
[0223] In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a 3-membered heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a 4-membered heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a 5-membered heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein. In certain embodiments, when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a 6-membered heterocyclyl, optionally substituted with one, two, three, four, or five substituents Q as described herein.
[0224] In certain embodiments, R7a is hydrogen. In certain embodiments, R7a is cyano. In certain embodiments, R7a is halo. In certain embodiments, R7a is fluoro, chloro, bromo, or iodo. In certain embodiments, R7a is nitro. In certain embodiments, R7a is Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is C2-6 alkenyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is C2-6 alkynyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is C3_7 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is C3_i0 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is phenyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is phenyl, optionally substituted with one or more substituents, each of which is selected independently from the group consisting of fluoro, chloro, bromo, methyl, and methoxy. In certain embodiments, R7a is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2- bromophenyl, 2-methylphenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl, 4- fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl. In certain embodiments, R7a is C7_i5 aralkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is monocyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is 5-membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is imidazolyl or pyrozolyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is imidazol-l-yl, pyrozol-4-yl, 1 -methyl -
pyrozol-4-yl, or 2-methylpyrozol-3-yl. In certain embodiments, R7a is 6-membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is pyridinyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methylpyridin-4-yl, or 2- methoxypyridin-4-yl. In certain embodiments, R7a is heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is monocyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is 5-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is piperidinyl or piperazinyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7a is l-methylpiperidin-4-yl, or 4-methylpiperazin-l -yl.
[0225] In certain embodiments, R7a is -C(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7a is -C(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7a is -C(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7a is -C(NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7a is -ORa, wherein Ra is as defined herein. In certain embodiments, Ra is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, Ra is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R7a is -OC(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7a is -OC(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7a is - OC(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7a is - OC(=NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7a is - OS(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7a is -OS(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7a is -OS(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7a is -OS(0)2NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7a is -NRbRc, wherein Rb and Rc are each as defined herein. In certain
embodiments, R7a is amino (-NH2). In certain embodiments, R7a is -NRaC(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7a is -NRaC(0)ORd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7a is -NRaC(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7a is -NRaC(=NRd)NRbRc, wherein Ra, Rb, Rc, and Rd are each as defined herein. In certain embodiments, R7a is -NRaS(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7a is -NRaS(0)2Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7a is -NRaS(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7a is -NRaS(0)2NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7a is -SRa, wherein Ra is as defined herein. In certain embodiments, R7a is -S(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7a is -S(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7a is -S(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7a is -S(0)2NRbRc; wherein Rb and Rc are each as defined herein.
[0226] In certain embodiments, R7a is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- (3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l-yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1- methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1- methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0227] In certain embodiments, is hydrogen. In certain embodiments, R7b is cyano. In certain embodiments, is halo. In certain embodiments, R^ is fluoro, chloro, bromo, or iodo. In certain embodiments, R^ is nitro. In certain embodiments, R^ is Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7b is C2_6 alkenyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R^ is C2-6 alkynyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7b is C3_i0 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R^ is C3_7 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R^ is C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R^ is C7_i5 aralkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7b is heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R^ is heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein.
[0228] In certain embodiments, R^ is -C(0)Ra, wherein Ra is as defined herein. In certain embodiments, R¾ is -C(0)ORa, wherein Ra is as defined herein. In certain embodiments, R^ is -C(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R^ is -C(NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7b is -ORa, wherein Ra is as defined herein. In certain embodiments, Ra is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, Ra is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R7b is -OC(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7b is -OC(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7" is -OC(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain
embodiments, R7" is -OC(=NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7" is -OS(0)Ra, wherein Ra is as defined herein. In certain embodiments, R^ is - OS(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7b is -OS(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7b is -OS(0)2NRbRc, wherein Rb and Rc are each
as defined herein. In certain embodiments, is -NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R^ is amino (-NH2). In certain embodiments, R^ is -NRaC(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7b is -NRaC(0)ORd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7b is -NRaC(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, is -NRaC(=NRd)NRbRc, wherein Ra, Rb, Rc, and Rd are each as defined herein. In certain embodiments, R7b is -NRaS(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R^ is -NRaS(0)2Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7b is -NRaS(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R¾ is -NRaS(0)2NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R^ is -SRa, wherein Ra is as defined herein. In certain embodiments, R^ is -S(0)Ra, wherein Ra is as defined herein. In certain embodiments, R^ is -S(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R^ is -S(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7" is -S(0)2NRbRc; wherein Rb and Rc are each as defined herein.
[0229] In certain embodiments, R^ is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7b is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- (3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1 - methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l -isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1 - methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0230] In certain embodiments, R7c is hydrogen. In certain embodiments, R7c is cyano. In certain embodiments, R7c is halo. In certain embodiments, R7c is fluoro, chloro, bromo, or iodo. In certain embodiments, R7c is nitro. In certain embodiments, R7c is Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is C2_6 alkenyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is C2_6 alkynyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is C3_i0 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is C3_7 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is C7_i5 aralkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7c is heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein.
[0231] In certain embodiments, R7c is -C(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7c is -C(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7c is -C(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7c is -C(NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7c is -ORa, wherein Ra is as defined herein. In certain embodiments, Ra is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, Ra is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R7c is -OC(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7c is -OC(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7c is - OC(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7c is - OC(=NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7c is - OS(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7c is -OS(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7c is -OS(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7c is -OS(0)2NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7c is -NRbRc, wherein Rb and Rc are each as defined herein. In certain
embodiments, R7c is amino (-NH2). In certain embodiments, R7c is -NRaC(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7c is -NRaC(0)ORd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7c is -NRaC(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7c is -NRaC(=NRd)NRbRc, wherein Ra, Rb, Rc, and Rd are each as defined herein. In certain embodiments, R7c is -NRaS(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7c is -NRaS(0)2Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7c is -NRaS(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7c is -NRaS(0)2NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7c is -SRa, wherein Ra is as defined herein. In certain embodiments, R7c is -S(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7c is -S(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7c is -S(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7c is -S(0)2NRbRc; wherein Rb and Rc are each as defined herein.
[0232] In certain embodiments, R7c is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- (3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l -yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1 - methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l -isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1 - methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0233] In certain embodiments, R7d is hydrogen. In certain embodiments, R7d is cyano. In certain embodiments, R7d is halo. In certain embodiments, R7d is fluoro, chloro, bromo, or iodo. In certain embodiments, R7d is nitro. In certain embodiments, R7d is Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is C2_6 alkenyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is C2-6 alkynyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is C3_i0 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is C3_7 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is C7_i5 aralkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7d is heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein.
[0234] In certain embodiments, R7d is -C(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7d is -C(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7d is -C(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7d is -C(NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7d is -ORa, wherein Ra is as defined herein. In certain embodiments, Ra is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, Ra is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R7d is -OC(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7d is -OC(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7d is -OC(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain
embodiments, R7d is -OC(=NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7d is -OS(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7d is - OS(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7d is -OS(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7d is -OS(0)2NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7d is -NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7d is amino (-NH2). In certain embodiments, R7d is -NRaC(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7d is -NRaC(0)ORd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7d is -NRaC(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7d is -NRaC(=NRd)NRbRc, wherein Ra, Rb, Rc, and Rd are each as defined herein. In certain embodiments, R7d is -NRaS(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7d is -NRaS(0)2Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7d is -NRaS(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7d is -NRaS(0)2NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7d is -SRa, wherein Ra is as defined herein. In certain embodiments, R7d is -S(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7d is -S(0)2Ra, wherein Ra is as defined herein.
In certain embodiments, R7d is -S(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7d is -S(0)2NRbRc; wherein Rb and Rc are each as defined herein.
[0235] In certain embodiments, R7d is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- (3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l-yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1- methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1- methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0236] In certain embodiments, R7e is hydrogen. In certain embodiments, R7e is cyano. In certain embodiments, R7e is halo. In certain embodiments, R7e is fluoro, chloro, bromo, or iodo. In certain embodiments, R7e is nitro. In certain embodiments, R7e is Ci_6 alkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is C2_6 alkenyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is C2-6 alkynyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is C3_i0 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is C3_7 cycloalkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is C7_i5 aralkyl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is heteroaryl, optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, R7e is heterocyclyl, optionally substituted with one, two, three, or four substituents Qa as described herein.
[0237] In certain embodiments, R7e is -C(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7e is -C(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7e is -C(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7e is -C(NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7e is -ORa, wherein Ra is as defined herein. In certain embodiments, Ra is -0-Ci_6 alkyl, wherein the alkyl is optionally substituted with one, two, three, or four substituents Qa as described herein. In certain embodiments, Ra is methoxy, ethoxy, propoxy, isopropoxy, or 3-dimethylaminopropoxy. In certain embodiments, R7e is -OC(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7e is -OC(0)ORa, wherein Ra is as defined herein. In certain embodiments, R7e is - OC(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7e is - OC(=NRa)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7e is - OS(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7e is -OS(0)2Ra, wherein Ra is as
defined herein. In certain embodiments, R7e is -OS(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7e is -OS(0)2NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7e is -NRbRc, wherein Rb and Rc are each as defined herein. In certain
embodiments, R7e is amino (-NH2). In certain embodiments, R7e is -NRaC(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7e is -NRaC(0)ORd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7e is -NRaC(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7e is -NRaC(=NRd)NRbRc, wherein Ra, Rb, Rc, and Rd are each as defined herein. In certain embodiments, R7e is -NRaS(0)Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7e is -NRaS(0)2Rd, wherein Ra and Rd are each as defined herein. In certain embodiments, R7e is -NRaS(0)NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7e is -NRaS(0)2NRbRc, wherein Ra, Rb, and Rc are each as defined herein. In certain embodiments, R7e is -SRa, wherein Ra is as defined herein. In certain embodiments, R7e is -S(0)Ra, wherein Ra is as defined herein. In certain embodiments, R7e is -S(0)2Ra, wherein Ra is as defined herein. In certain embodiments, R7e is -S(0)NRbRc, wherein Rb and Rc are each as defined herein. In certain embodiments, R7e is -S(0)2NRbRc; wherein Rb and Rc are each as defined herein.
[0238] In certain embodiments, R7e is phenyl, imidazolyl, pyrozolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7e is phenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-methylphenyl, 2- (3-dimethylaminopropyl)phenyl, 2-methoxyphenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3- methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-fluoro-3-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-morpholin-4- ylmethylphenyl, imidazol-l-yl, pyrozol-4-yl, 1 -methyl -pyrozol-4-yl, 2-methylpyrozol-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-fluoropyridin-3-yl, 2-methylpyridin-4-yl, 2-(4-methylpiperazin-l-yl)pyridin- 4-yl, 2-methoxypyridin-4-yl, pyrimidin-5-yl, pyrrolidin-3-yl, l-methylpyrrolidin-3-yl, piperidin-4-yl, 1- methylpiperidin-4-yl, l-ethylpiperidin-4-yl, l-isopropylpiperidin-4-yl, 1 -acetylpiperidin-4-yl, 1- methylsulfonylpiperidin-4-yl, or 4-methylpiperazin-l-yl.
[0239] In certain embodiments, R7a and R7b together with the carbon atoms to which they are attached form C3-io cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R^ together with the carbon atoms to which they are attached form C3_i0 cycloalkenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R7b together with the carbon atoms to which they are attached form cyclohexenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R7b together with the carbon atoms to which they are attached form C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R^ together with the carbon atoms to which they are attached form phenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R^ together with the carbon atoms to which they are attached form heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R^ together with the carbon atoms to which they are attached form
monocyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R7b together with the carbon atoms to which they are attached form 5- or 6- membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R7b together with the carbon atoms to which they are attached form bicyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and together with the carbon atoms to which they are attached form heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and together with the carbon atoms to which they are attached form monocyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R^ together with the carbon atoms to which they are attached form 5- or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7a and R^ together with the carbon atoms to which they are attached form bicyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa.
[0240] In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form C3-io cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7b and R7c together with the carbon atoms to which they are attached form C3_i0 cycloalkenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form cyclohexenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form phenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7b and R7c together with the carbon atoms to which they are attached form monocyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form 5- or 6- membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form bicyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7b and R7c together with the carbon atoms to which they are attached form heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7b and R7c together with the carbon atoms to which they are attached form monocyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form 5- or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R^ and R7c together with the carbon atoms to which they are attached form bicyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa.
[0241] In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form C3_io cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form C3_i0 cycloalkenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form cyclohexenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form C6_i4 aryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form phenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form monocyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form 5- or 6- membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form bicyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form monocyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form 5- or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7c and R7d together with the carbon atoms to which they are attached form bicyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa.
[0242] In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form C3-io cycloalkenyl, C6_i aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form C3_i0 cycloalkenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form cyclohexenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form C6_i aryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form phenyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form monocyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain
embodiments, R7d and R7e together with the carbon atoms to which they are attached form a 5 - or 6- membered heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form bicyclic heteroaryl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form monocyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form 5- or 6-membered heterocyclyl, optionally substituted with one, two, three, or four substituents Qa. In certain embodiments, R7d and R7e together with the carbon atoms to which they are attached form bicyclic heterocyclyl, optionally substituted with one, two, three, or four substituents Qa.
[0243] In certain embodiments, m is 0. In certain embodiments, m is 1.
[0244] In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 0, 1, or 2. In certain embodiments, n is 0, 1, 2, or 3. In certain embodiments, n is 1, 2, or 3. In certain embodiments, n is 1 or 2.
[0245] In certain embodiments, m is 0, and n is 0, 1, 2, or 3. In certain embodiments, m is 0, and n is 0, 1, or 2. In certain embodiments, m is 0, and n is 0 or 1. In certain embodiments, m is 0, and n is 0. In certain embodiments, m is 0, and n is 1. In certain embodiments, m is 1, and n is 0, 1, 2, or 3. In certain embodiments, m is 1, and n is 0, 1, or 2. In certain embodiments, m is 1, and n is 0 or 1. In certain embodiments, m is 1, and n is 0. In certain embodiments, m is 1, and n is 1.
[0246] In specific embodiments, m is 0, n is l, and R5a and R5b are each methyl.
[0247] In certain embodiments, X is N In certain embodiments, X is CRX, wherein Rx is as defined herein. In certain embodiments, X is CH.
[0248] In certain embodiments, Y is N In certain embodiments, Y is CRX, wherein Rx is as defined herein. In certain embodiments, Y is CH.
[0249] In certain embodiments, Z is N In certain embodiments, Z is CRX, wherein Rx is as defined herein. In certain embodiments, Z is CH.
[0250] In certain embodiments, X, Y, and Z are N. In certain embodiments, X and Y are N, and Z is CH. In certain embodiments, X and Z are N, and Y is CH. In certain embodiments, Y and Z are N, and X is CH.
[0251] In certain embodiments, the compound provided herein is not 4-(2-(difluoromethyl)-lH- benzo[<f]imidazol-l-yl)-6-mo holino-N-(2 -phenyl -2-(pyrrolidin-l-yl)ethyl)-l,3,5-triazin-2 -amine. In certain embodiments, the compound provided herein is not 6-(2-(difluoromethyl)-lH-benzo[£f]imidazol-l- yl)-N-(l-(4-(( ?)-3-(methoxymethyl)mo holino)phenyl)ethyl)-2-mo holinopyrimidin-4-amine.
[0252] In certain embodiments, when X, Y, and Z are Ν, and R5a is hydrogen, R5b is not heterocyclyl. In certain embodiments, when X, Y, and Z are Ν, and R5a is hydrogen, R5b is not 5-membered heterocyclyl.
In certain embodiments, when X, Y, and Z are N, and R5a is hydrogen, R5b is not pyrrolidinyl. In certain embodiments, when X, Y, and Z are N, and R5a is hydrogen. R5b is not pyrrolidin-l-yl.
[0253] In certain embodiments, when X and Z are N, Y is CH. and R5a is hydrogen, R5b is morpholino- substituted phenyl. In certain embodiments, when X and Z are N, Y is CH, and R5a is hydrogen, R5b is not 4-((i?)-3 -(methoxymethyl)morpholino)phenyl .
[0254] In one embodiment, provided herein is a compound selected from:
Compound V, Compound VI,
Compound XV, and
Compound XVI.
[0255] In one embodiment, the PI3K inhibitor is Compound I, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound II, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound III, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound IV, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one
embodiment, the PI3K inhibitor is Compound V, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound VI, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one
embodiment, the PI3K inhibitor is Compound VII, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound VIII, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one
embodiment, the PI3K inhibitor is Compound IX, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound X, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one
embodiment, the PI3K inhibitor is Compound XI, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound XII, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one
embodiment, the PI3K inhibitor is Compound XIII, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound XIV, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one
embodiment, the PI3K inhibitor is Compound XV, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In one embodiment, the PI3K inhibitor is Compound XVI, or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
PD-1 andPD-Ll Inhibitors
[0256] Described herein are PI3K inhibitors in combination with PD-1 or PD-L 1 inhibitors.
[0257] The PD-1 (programmed cell death - 1) receptor (also known as CD279) is expressed on the surface of activated T cells. Its ligand, PD-L1, is commonly expressed on the surface of dendritic cells or
macrophages. In some instances, PD 1 and PD-Ll interaction halts or limits the development of the T cell response. When PD-Ll binds to PD-1, an inhibitory signal is transmitted into the T cell, which reduces cytokine production and suppresses T-cell proliferation. In some instances, cancer or tumor cells exploit this signaling pathway as a mechanism to evade detection and inhibit the immune response. In some instances, PD-Ll is overexpressed on cancer or tumor cells or on non -transformed cells in the tumor microenvironment. In some instances, PD-Ll expressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. These deactivated T cells remain inhibited in the tumor microenvironment. The PD 1/PD-L1 pathway represents an adaptive immune resistance mechanism that is exerted by cancer or tumor cells in response to endogenous anti -tumor activity.
[0258] PD-1 inhibitors (or anti -PD-1 agents) and PD-Ll inhibitors (or anti -PD-Ll agents) block the interaction between PD-1 and PD-Ll and boost the immune response against cancer cells. In some instances, the blockade of receptor engagement results in the amplification of antigen-specific T cell responses against cancer cells. In some instances, antibodies that block the PD-1/PD-L 1 interaction target lymphocyte receptors or their ligands in order to enhance endogenous antitumor activity. In some instances, PD-1 inhibitors and PD-Ll inhibitors overcome distinct immune suppressive pathways within the tumor microenvironment. In some instances, PD-1 inhibitors and/or PD-L l inhibitors are useful for treating cancer.
[0259] Any suitable PD-1 inhibitor or PD-Ll inhibitor may be used in combination with a PI3K inhibitor described herein. In some embodiments, the PD-1 inhibitor is an antagonist of PD-1. In some
embodiments, the PD-Ll inhibitor is an antagonist of PD-Ll . In some embodiments, the PD-1 inhibitor or PD-Ll inhibitor is an antibody, variant, or biosimilar thereof. In some embodiments, the PD-1 inhibitor or PD-Ll inhibitor is a monoclonal antibody. In some embodiments, the method of treating cancer with a PI3K inhibitor described herein in combination with a PD-1 or PD-Ll inhibitor results in a transient reduction in the level of systemic immunosuppression.
[0260] Some embodiments provided herein describe a pharmaceutical compositions or methods for use the pharmaceutical compositions comprising a PI3K inhibitor described herein in combination with a PD- 1 inhibitor. PD-1 inhibitors for use in pharmaceutical compositions and methods provided herein include, but are not limited to, nivolumab (Opdivo®), pembrolizumab (Keytruda®), MEDI0680 (AMP-514), AMP-224, AMP-514 (Amplimmune), BGB-A317, PDR001, REGN2810, JS001, AGEN2034, and variants and biosimilars thereof. In some embodiments, the PD-1 inhibitor is to nivolumab (Opdivo®), pembrolizumab (Keytruda®), MEDI0680 (AMP-514), AMP-224, AMP-514 (Amplimmune), or variants or biosimilars thereof. In some embodiments, the PD-1 inhibitor is pidilzumab (CT-01 1), or a variant or biosimilar thereof. In some embodiments, the PD-1 inhibitor is nivolumab (Opdivo®), or pembrolizumab (Keytruda®), or a variant or biosimilar thereof. In some embodiments, the PD-1 inhibitor is nivolumab (Opdivo®), a nivolumab variant, or a nivolumab biosimilar. In some embodiments, the PD-1 inhibitor is pembrolizumab (Keytruda®), a pembrolizumab variant, or a pembrolizumab biosimilar. In some embodiments, the PD-1 inhibitor is BGB-A317, a BGB-A317 variant, or a BGB-A317 biosimilar. In
some embodiments, the PD-1 inhibitor is PDR001, a PDR001 variant, or a PDR001 biosimilar. In some embodiments, the PD-1 inhibitor is REGN2810, a REGN2810 variant, or a REGN2810 biosimilar.
[0261] Some embodiments provided herein describe pharmaceutical compositions or methods for using the pharmaceutical compositions comprising a PI3K inhibitor described herein in combination with a PD- Ll inhibitor. PD-Ll inhibitors for use in pharmaceutical compositions and methods provided herein include but are not limited to Atezolizumab (Tecentriq® or MPDL3280A), avelumab (Bavencio®), Durvalumab (MEDI4736), MPDL3280A (RG7446), BMS-936559 (MDX-1 105), MSB0010718C, YW243.55.S70, and variants and biosimilars thereof. In some embodiments, the PD-L l inhibitor is Atezolizumab (Tecentriq® or MPDL3280A), avelumab (Bavencio®), or Durvalumab (MEDI4736), or variants or biosimilars thereof. In some embodiments, the PD-Ll inhibitor is Atezolizumab (Tecentriq® or MPDL3280A) or avelumab (Bavencio®), or a variant or biosimilar thereof. In some embodiments, the PD-Ll inhibitor is atezolizumab (Tecentriq® or MPDL3280A), an atezolizumab variant, or an
atezolizumab biosimilar. In some embodiments, the PD-Ll inhibitor is avelumab (Bavencio®), avelumab variant, or an avelumab biosimilar. In some embodiments, the PD-Ll inhibitor is BMS-936559 (MDX- 1 105), BMS-936559 variant, or a BMS-936559 biosimilar. In some embodiments, the PD-L l inhibitor is durvalumab (MEDI4736), a durvalumab variant, or a durvalumab biosimilar.
[0262] In some embodiments, the compounds of Formula (I), or isotopic variants, pharmaceutically acceptable salts, solvates, hydrates, or prodrugs thereof, demonstrate higher avidity and biologic activity for a PI3K (e.g., PI3K5) compared to other PI3K inhibitors, including but not limited to idelalisib. In some embodiments, the compounds of Formula (I), or isotopic variants, pharmaceutically acceptable salts, solvates, hydrates, or prodrugs thereof, demonstrate improved or superior drug distribution to blood cells compared to other PI3K inhibitors, including but not limited to idelalisib.
[0263] In some embodiments, the combination therapy of a PD-1 or PD-L l inhibitor and a compound of Formula (I), or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, shows low toxicity to normal cells. In various embodiments, the combination of a compound of Formula (I), or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and a PD- 1 or PD-Ll inhibitor is selectively toxic or more toxic to rapidly proliferating cells, e.g., cancerous tumors, than to normal cells.
[0264] In some embodiments, the combination therapy described herein avoids or reduces adverse or unwanted, serious, or fatal side effects associated with the use of a PI3K inhibitor (e.g., idelalisib) and/or a PD-1 or PD-Ll inhibitor. In some embodiments, the combination therapy described herein avoids, reduces, or minimizes (serious) infections, neutropenia, (severe) diarrhea, colon inflammation, colitis, lung tissue inflammation (pneumonitis), intestinal perforation, pneumonia, anemia, thrombocytopenia, nausea, fever, fatigue, cough, abdominal pain, chills, rash, vomiting, hypertriglyceridemia, hyperglycemia, elevated levels of liver enzymes (e.g., ALT and ALST), liver toxicity, swelling in extremities, or a combination thereof in patients receiving the combination therapy. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of infection, including serious infection. In certain embodiments, the combination therapy described herein avoids, reduces, or
minimizes the incidence of neutropenia. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of diarrhea, including severe diarrhea. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of colon inflammation. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of colitis. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of lung tissue inflammation (pneumonitis). In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of intestinal perforation. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of pneumonia. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of anemia. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of thrombocytopenia. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of nausea. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of fever. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of fatigue. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of cough. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of abdominal pain. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of chills. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of rash. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of vomiting. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of hypertriglyceridemia.
[0265] In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of hyperglycemia. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of elevated levels of liver enzymes (e.g., ALT and ALST). In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of liver toxicity. In certain embodiments, the combination therapy described herein avoids, reduces, or minimizes the incidence of swelling in the extremities.
[0266] In some embodiments, the combination therapy described herein avoids or reduces adverse or unwanted side effects associated with chemotherapy, radiotherapy, or cancer therapy. In some instances, the combination therapies and/or compositions described herein provide chemo-protective and/or radioprotective properties to non-cancerous cells. In further or additional embodiments, the lower
amount/doses of PI3K inhibitor reduces or minimizes any undesired side-effects associated with chemotherapy. Non-limiting examples of side-effects associated with chemotherapy, radiotherapy, or cancer therapy include fatigue, anemia, appetite changes, bleeding problems, diarrhea, constipation, hair loss, nausea, vomiting, pain, peripheral neuropathy, swelling, skin and nail changes, urinary and bladder changes, and trouble swallowing.
Methods of Use
[0267] Some embodiments provided herein describe a method for treating or preventing a proliferative disease or disorder comprising administering a PI3K inhibitor in combination with a PD-1 inhibitor or a PD-Ll inhibitor. In certain embodiments, provided herein are methods for treating or preventing a disease comprising administering an effective amount of a compound of Formula (I), or an isotopic variant thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and an effective amount of a PD-1 or PD-Ll inhibitor. In some embodiments, the compound of Formula (I) is Compound I or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound II or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound III or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound IV or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound V or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound VI or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound VII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound VIII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound IX or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound X or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XI or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XIII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XIV or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XV or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XVI or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the PD-1 or PD-Ll inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, BGB-A317, PDR001, REGN2810, or durvalumab. In other embodiments, the PD- 1 or PD-L 1 inhibitor is nivolumab, pembrolizumab, atezolizumab, BGB-A317, PDROO 1 , REGN2810, or avelumab. In some embodiments, the PD-1 or PD-Ll inhibitor is pidilizumab, nivolumab,
pembrolizumab, atezolizumab, avelumab, BMS-936559, or durvalumab. In other embodiments, the PD-1 or PD-Ll inhibitor is nivolumab, pembrolizumab, atezolizumab, or avelumab.
[0268] In some embodiments, the proliferative disease is cancer. In certain embodiments, the proliferative disease is hematological cancer. In certain embodiments, the proliferative disease is a cancer of the breast, skin, prostate, cervix, uterus, ovary, testes, bladder, lung, liver, larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus, stomach, pancreas), brain, thyroid, blood, and lymphatic system.
[0269] In certain embodiments, the cancer treatable with the methods provided herein includes, but is not limited to, (1) leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome or a symptom thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia or pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T), preleukemia, and chronic myelomonocytic leukemia (CMML), (2) chronic leukemias, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, and hairy cell leukemia; (3) polycythemia vera; (4) lymphomas, including, but not limited to, Hodgkin's disease and non-Hodgkin's disease; (5) multiple myelomas, including, but not limited to, smoldering multiple myeloma, non- secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; (6) Waldenstrom's macroglobulinernia; (7) monoclonal gammopathy of undetermined significance; (8) benign monoclonal gammopathy; (9) heavy chain disease; (10) bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft- tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; (11) brain tumors, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, aligodendrogliorna, nonglial tumor, acoustic neurinoma, craniopharyngioma,
medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; (12) breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mutinous breast cancer, tubular breast cancer, papillary breast cancer, primary cancers, Paget' s disease, and inflammatory breast cancer; (13) adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; (14) thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; (15) pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; (16) pituitary cancer, including, but limited to, Cushing's disease, prol actin-secreting tumor, acromegaly, and diabetes insipius; (17) eye cancer, including, but not limited, to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; (18) vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; (19) vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget 's disease; (20) cervical cancers, including, but not limited to, squamous cell carcinoma, and
adenocarcinoma; (21) uterine cancer, including, but not limited to, endometrial carcinoma and uterine
sarcoma; (22) ovarian cancer, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; (23) esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma,
adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; (24) stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; (25) colon cancer; (26) rectal cancer; (27) liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma; (28) gallbladder cancer, including, but not limited to, adenocarcinoma; (29) cholangiocarcinomas, including, but not limited to, pappillary, nodular, and diffuse; (30) lung cancer, including, but not limited to, non -small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma, and small-cell lung cancer; (31) testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical),
spermatocyte, nonserninoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); (32) prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; (33) penal cancer; (34) oral cancer, including, but not limited to, squamous cell carcinoma; (35) basal cancer; (36) salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; (37) pharynx cancer, including, but not limited to, squamous cell cancer and verrucous; (38) skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; (39) kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterer); (40) Wilms' tumor; (41) bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosarcoma; (42)
reproductive cancers, such as cervical cancer, uterus cancer, ovarian cancer, or testicular cancer; (43) esophagus cancer; (44) laryngeal cancer; (45) head and neck cancer (such as mouth, nose, throat, larynx, sinuses, or salivary glands cancer); and other cancer, including, not limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio-endotheliosarcoma, mesothelioma, synovioma,
hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinomas (See Fishman et al , 1985 , Medicine , 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al , 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America). In some embodiments, the cancer is non-small cell lung cancer, melanoma, renal cell cancer, head and neck cancer, colon cancer, or mesothelioma. In some embodiments, the cancer is non-small cell lung cancer. In some embodiments, the cancer is melanoma.
[0270] In certain embodiments, provided herein are methods of treating a hematological malignancy with a combination of an effective amount of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and an effective amount of PD-1 or
PD-L1 inhibitor in a patient. In certain embodiments, the hematological malignancy is a leukemia, a lymphoma, a myeloma, a non-Hodgkin's lymphoma, a Hodgkin's lymphoma, T-cell malignancy, or a B- cell malignancy. In some embodiments, the hematological malignancy is Hodgkin's lymphoma. In some embodiments, the hematological malignancy is chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma. In some embodiments, the hematological malignancy is chronic lymphocytic leukemia or non-Hodgkin's lymphoma. In some embodiments, the hematological malignancy is chronic lymphocytic leukemia. In other embodiments, the hematological malignancy is non-Hodgkin's lymphoma. In some embodiments, the hematological malignancy is follicular lymphoma. In other embodiments, the hematological malignancy is diffuse large B-cell lymphoma. In some embodiments, the compound of Formula (I) is Compound I or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound II or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound III or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound IV or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound V or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound VI or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound VII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound VIII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound IX or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound X or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XI or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XIII or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XIV or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XV or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the compound of Formula (I) is Compound XVI or an isotopic variant, pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0271] In certain embodiments, the hematological malignancy is a T-cell malignancy. In certain embodiments, T-cell malignancies include peripheral T-cell lymphoma not otherwise specified (PTCL- NOS), anaplastic large cell lymphoma, angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult
T-cell leukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-type T-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma, lymphoblastic lymphoma, nasal NK/T-cell lymphomas, or treatment-related T-cell lymphomas.
[0272] In certain embodiments, the hematological malignancy is a B-cell malignancy. In certain embodiments, B-cell malignancies include acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMoL), chronic lymphocytic leukemia (CLL), high-risk chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high-risk small lymphocytic lymphoma (SLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B -lymphoblastic lymphoma, B cell prolymphocyte leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis. In certain embodiments, the B-cell malignancy is diffuse large B-cell lymphoma (DLBCL). In certain embodiments, the hematological malignancy is diffuse large B-cell lymphoma (DLBCL). In certain embodiments, the DLBCL is an activated B-cell DLBCL (ABC-DLBCL), a germinal center B-cell like DLBCL (GBC-DLBCL), a double hit DLBCL (DH-DLBCL), or a triple hit DLBCL (TH-DLBCL). In certain embodiments, the hematological malignancy is relapsed-refractory diffuse large B-cell lymphoma (r/r DLBCL).
[0273] In certain embodiments, the hematological malignancy is a relapsed or refractory hematological malignancy. In certain embodiments, the relapsed or refractory hematological malignancy is a relapsed or refractory T-cell malignancy. In certain embodiments, the relapsed or refractory hematological malignancy is a relapsed or refractory B-cell malignancy.
[0274] Depending on the disorder, disease, or condition to be treated, and the subject's condition, the compounds or pharmaceutical compositions provided herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracistemal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration and can be formulated, alone or together, in suitable dosage unit with pharmaceutically acceptable excipients, carriers, adjuvants, and vehicles appropriate for each route of administration as described elsewhere herein.
Dosages and Dosing Regimens
[0275] In certain embodiments, the methods provided herein comprise administering a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-L1 inhibitor to a patient simultaneously or sequentially by the same or different routes of administration.
[0276] The suitability of a particular route of administration employed for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally without decomposing prior to
entering the blood stream) and the disease being treated. Recommended routes of administration for the second active agents are known to those of ordinary skill in the art. See, e.g. , Physicians' Desk Reference, 1755-1760 (56th ed., 2002).
[0277] In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor are administered simultaneously, at essentially the same time, or sequentially. If administration takes place sequentially, the PD-1 or PD-Ll inhibitor may be administered before or after administration of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the PD-1 or PD-Ll inhibitor is administered before administration of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the PD-1 or PD-Ll inhibitor is administered simultaneously with administration of a compound of Formula (I), an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. In some embodiments, the PD-1 or PD-Ll inhibitor is administered after the administration of a compound of Formula (I), an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0278] In certain embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and the PD-1 or PD-Ll inhibitor need not be administered by means of the same vehicle. In some embodiments, the PD-1 or PD-Ll inhibitor and a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof are administered in different vehicles. The PD-1 or PD-Ll inhibitor may be administered one or more times, and the number of administrations of each component of the combination may be the same or different. In addition, a compound of Formula (I), or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and the PD-1 or PD-Ll inhibitor need not be administered at the same site.
[0279] In some instances, the methods described herein further comprise administering the PI3K inhibitor in combination with PD-1 or PD-Ll inhibitor to the subject or patient in need thereof in multiple cycles repeated on a regular schedule with periods of rest in between each cycle . For example, in some instances, treatment is given for one week followed by three weeks of rest is one treatment cycle.
[0280] In some instances, a cycle comprises administration of the PI3K inhibitor at the same time as administration of the PD-1 or PD-Ll inhibitor. In some instances, the PI3K inhibitor and the PD-1 or PD- Ll inhibitor are administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 1 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, or about 28 days.
[0281] In some instances, a cycle comprises administration of the PI3K inhibitor first followed by administration of the PD-1 or PD-Ll inhibitor second. In some instances, the PI3K inhibitor is administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about
7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days followed by administration of the PD-1 or PD-Ll inhibitor for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.
[0282] In some instances, a cycle comprises administration of the PI3K inhibitor first followed by concurrent administration of the PD-1 or PD-Ll inhibitor. In some instances, the PI3K inhibitor is first administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about
7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days followed by the concurrent administration of the PD-1 or PD-Ll inhibitor for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days. In some instances, the PI3K inhibitor is first administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days followed by the concurrent administration of the PD-1 or PD-Ll inhibitor for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about
8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days. In some instances, the PI3K inhibitor is first administered for about 7 days followed by the concurrent administration of the PD-1 or PD-Ll inhibitor for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about
12 days, about 13 days, or about 14 days. In some instances, the PI3K inhibitor is first administered for about 7 days followed by the concurrent administration of the PD-1 or PD-Ll inhibitor for about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.
[0283] In some instances, a cycle comprises administration of the PI3K inhibitor only. In some instances, the PI3K inhibitor is administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about
13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, or about 28 days.
[0284] In some instances, a cycle comprises administration of the PD-1 or PD-Ll inhibitor only. In some instances, the PD-1 or PD-Ll inhibitor is administered for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, or about 28 days.
[0285] In some instances, the method for multiple cycle chemotherapy comprises the administration of a second cycle within about 60 days or about 3 months. In some instances, the method for multiple cycle chemotherapy comprises the administration of a second cycle within 50 days. In another instance, the second cycle is administered within 45, 40, 35, 30, 25, 21, 20, 15, 14, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 day(s) of the first cycle. In some embodiments, the administration of any additional cycles is within 50 days of
the previous cycle. In some embodiments, the administration of any additional cycles is within 10 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 9 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 8 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 7 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 6 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 5 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 4 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 3 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 2 days of the previous cycle. In some embodiments, the administration of any additional cycles is within 1 day of the previous cycle. In another embodiment, the additional cycle is administered within 45, 40, 35, 30, 25, 21, 20, 15, 14, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 days of the previous cycle.
[0286] The length of a treatment cycle depends on the treatment being given. In some embodiments, the length of a treatment cycle ranges from two to six weeks. In some embodiments, the length of a treatment cycle ranges from four to six weeks. In some embodiments, the length of a treatment cycle is 28 days. In some embodiments, the length of a treatment cycle is 56 days. In some embodiments, a treatment cycle lasts one, two, three, or four weeks. In some embodiments, a treatment cycle lasts four weeks. The number of treatment doses scheduled within each cycle also varies depending on the drugs being given.
[0287] In some instances, the method for the administration of multiple compounds comprises administering compounds within 48 hours or less of each other. In some embodiments administration occurs within 24 hours, 12 hours, 6 hours, 3 hours, 1 hour, or 15 minutes. In some instances, the compounds are administered simultaneously. One example of simultaneous administration is the injection of one compound immediately before, after, or during the oral administration of the second compound, immediately referring to a time less than about 5 minutes.
[0288] In some instances, the method for the administration of multiple compounds occurs in a sequential order, wherein the PI3K inhibitor is administered before the PD-1 or PD-L1 inhibitor. In another instance, the PD-1 or PD-L1 inhibitor is administered before the PI3K inhibitor.
[0289] In some instances, the method for administering the PI3K inhibitor is oral and the method for administering the PD-1 or PD-L1 inhibitor is by injection. In some instances, the method for
administering the PI3K inhibitor is by inhalation and the method for administering the PD-1 or PD-L1 inhibitor is by injection. In some instances, the method for administering the PI3K inhibitor is by injection and the method for administering the PD-1 or PD-L1 inhibitor is by injection.
[0290] In certain embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-L1 inhibitor are cyclically administered to a patient. As discussed above, cycling therapy involves the administration of an active agent or a combination of active agents for a period of time, followed by a rest for a period of time, and repeating this sequential administration. In some embodiments, cycling therapy reduces the
development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.
[0291] In some embodiments, the compound of Formula (I) is administered daily, every other day, every other day 3 times a week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 3 days, every 4 days, every 5 days, every 6 days, weekly, bi-weekly, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months. In some
embodiments, the compound of Formula (I) is administered daily.
[0292] In some embodiments, the PD-1 or PD-L1 inhibitor is administered daily, every other day, every other day 3 times a week, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, bi-weekly, 3 times a week, 4 times a week, 5 times a week, 6 times a week, once a month, twice a month, 3 times a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months.
[0293] In some instances, the compound of Formula (I) or the PD-1 or PD-L 1 inhibitor is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday"). In some embodiments, the length of the drug holiday varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 12 days, 14 days, 15 days, 20 days, 21 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%- 100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[0294] In certain embodiments, in the treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions described herein, an appropriate dosage level of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof generally is ranging from about 1 to about 1000 mg, from about 1 to about 500 mg, from about 5 to about 500 mg, from about 5 to about 200 mg, from about 5 to about 250 mg or from about 10 to about 150 mg which can be administered in single or multiple doses. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 1 10, 1 15, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 450 or 500 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 1 10, about 1 15, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 225,
about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 450, or about 500 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a
pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 30 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 45 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 60 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 90 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 120 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 180 mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 450 or 500 mg/day. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 30 mg/day. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 45 mg/day. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 60 mg/day. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 90/day mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 120/day mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 150/day mg. In certain embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered in an amount of about 180/day mg.
[0295] For oral administration, the pharmaceutical compositions provided herein can be formulated in the form of tablets or capsules containing from about 1.0 to about 1,000 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in one embodiment, about 1, about 5, about 10, about 15, about 20, about 25, about 50, about 75,
about 100, about 150, about 200, about 250, about 300, about 400, about 500, about 600, about 750, about 800, about 900, and about 1,000 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for the symptomatic adjustment of the dosage to the patient to be treated. In some embodiments, the pharmaceutical compositions provided herein can be formulated in the form of tablets containing about 60 mg of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The pharmaceutical compositions can be administered on a regimen of 1 to 4 times per day, including once, twice, three times, and four times per day. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, about 30 mg, about 45 mg, or about 60 mg of the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered once per day. In some embodiments, the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of about 60 mg daily for 28 days or 56 days. In certain specific embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of about 60 mg daily for 28 days. In other specific embodiments, a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to a patient in need thereof in an amount of about 60 mg daily for 56 days.
[0296] In the methods of treatment, prevention, or amelioration of one or more symptoms of the disorders, diseases, or conditions described herein, an appropriate dosage level of a PD-1 or PD-L1 inhibitor generally is ranging from about 0.1 to 2000 mg per day. In some embodiments, 1-500 mg once or multiple times per day is effective to obtain the desired results.
[0297] In certain embodiments, the PD-1 or PD-L1 inhibitor is pidilizumab and the amount of pidilizumab that is administered is from about 10 mg/day up to, and including, 1000 mg/day. In certain embodiments, the amount of pidilizumab that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of pidilizumab that is administered is from about 100 mg/day to 600 mg/day. In certain embodiments, the amount of pidilizumab that is administered per day is about 10 mg, about 50 mg, about 100 mg, about 120 mg, about 240 mg, about 420 mg or about 560 mg.
[0298] In certain embodiments, the methods described herein further comprise administering pidilizumab intravenously at a dosage of 1-10 mg/kg each week. In certain embodiments, pidilizumab is administered intravenously at a dosage of 3 mg/kg each week. In another embodiment, pidilizumab is administered intravenously at a dosage of about 100 mg, about 150 mg, about 240 mg, about 360 mg or about 450 mg each week.
[0299] In certain embodiments, the PD-1 or PD-L1 inhibitor is nivolumab and the amount of nivolumab that is administered is from about 10 mg/day up to, and including, 1000 mg/day. In certain embodiments, the amount of nivolumab that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of nivolumab that is administered is from about 100 mg/day to 600 mg/day. In
certain embodiments, the amount of nivolumab that is administered per day is about 10 mg, about 60 mg, about 120 mg, about 180 mg, about 240 mg, about 420 mg or about 560 mg.
[0300] In certain embodiments, the methods described herein further comprise administering nivolumab intravenously at a dosage of 1-10 mg/kg every two weeks. In certain embodiments, nivolumab is administered intravenously at a dosage of 3 mg/kg every two weeks. In certain embodiments, 3 mg/kg of nivolumab is administered as an intravenous infusion over 60 minutes every two weeks. In another embodiment, the amount of nivolumab that is administered is about 100 mg, about 150 mg, about 240 mg, about 360 mg or about 450 mg every two weeks.
[0301] In certain embodiments, the PD-1 or PD-L1 inhibitor is pembrolizumab and the amount of pembrolizumab that is administered is from about 10 mg/day up to, and including, 1000 mg/day. In certain embodiments, the amount of pembrolizumab that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of pembrolizumab that is administered is from about 100 mg/day to 600 mg/day. In certain embodiments, the amount of pembrolizumab that is administered per day is about 10 mg, about 60 mg, about 120 mg, about 180 mg, about 240 mg, about 420 mg or about 560 mg.
[0302] In certain embodiments, the methods described herein further comprise administering
pembrolizumab intravenously at a dosage of 1-10 mg/kg every three weeks. In certain embodiments, pembrolizumab is administered intravenously at a dosage of 2 mg/kg every three weeks. In certain embodiments, 2 mg/kg of pembrolizumab is administered as an intravenous infusion over 30 minutes every three weeks. In another embodiment, the amount of pembrolizumab that is administered is about 50 mg, about 100 mg, about 200 mg, about 300 mg or about 400 mg every three weeks.
[0303] In certain embodiments, the PD-1 or PD-L1 inhibitor is BGB-A317 and BGB-A317 is administered to a subject in need thereof with doses ranging from 0.5 to 10 mg/kg. In some embodiments, BGB-A317 is administered at a dosage of about 2 mg/kg or about 5 mg /kg. In some embodiments, BGB- A317 is administered at a dosage of about 2 mg/kg. In some embodiments, BGB-A317 is administered at a dosage of about 5 mg /kg.
[0304] In certain embodiments, the PD-1 or PD-L1 inhibitor is BGB-A317 and BGB-A317 is administered to a subject in need thereof with biweekly intravenous doses ranging from 0.5 to 10 mg/kg. In some embodiments, BGB-A317 is administered biweekly at a dosage of about 2 mg/kg or about 5 mg /kg. In some embodiments, BGB-A317 is administered biweekly at a dosage of about 2 mg/kg. In some embodiments, BGB-A317 is administered biweekly at a dosage of about 5 mg/kg. In some embodiments, BGB-A317 is administered biweekly at a dosage of about 2 mg/kg or about 5 mg /kg intravenously.
[0305] In some embodiments, BGB-A317 is administered intravenously once every three weeks at a dose ranging from about 0.5 to 10 mg/kg. In some embodiments, BGB-A317 is administered once every three weeks at a dosage of about 2 mg/kg or about 5 mg /kg. In some embodiments, BGB-A317 is
administered once every three weeks at a dosage of about 2 mg/kg. In some embodiments, BGB-A317 is administered once every three weeks at a dosage of about 5 mg/kg. In some embodiments, BGB-A317 is administered once every three weeks at a dosage of about 2 mg/kg or about 5 mg /kg intravenously.
[0306] In some embodiments, BGB-A317 is administered to the subject in need thereof in an amount of about 200 mg or 300 mg. In some embodiments, BGB-A317 is administered to the subject in need thereof in an amount of about 200 mg once every two weeks. In some embodiments, BGB-A317 is administered to the subject in need thereof in an amount of about 300 mg once every two weeks. In some embodiments, BGB-A317 is administered to the subject in need thereof in an amount of about 200 mg once every three weeks. In some embodiments, BGB-A317 is administered to the subject in need thereof in an amount of about 300 mg once every three weeks.
[0307] In some embodiments, the PD-1 or PD-L1 inhibitor is PDR001 and PDR001 is administered to a subject in need thereof via intravenous infusion over 30 mins. In other embodiments, PDR001 is administered to a subject in need thereof via intravenous infusion for up to 2 hours. In some
embodiments, PDR001 is administered to a subject in need thereof once every 4 or 8 weeks. In certain embodiments, PDR001 is administered to a subject in need thereof once every 4 weeks. In other embodiments, PDR001 is administered to a subject in need thereof once every 8 weeks.
[0308] In some embodiments, the PD-1 or PD-L1 inhibitor is REGN2810 and REGN2810 is administered to a subject in need thereof intravenously every 2 weeks. In some embodiments,
REGN2810 is administered to a subject in need thereof in an amount of about 200 mg. In some embodiments, REGN2810 is administered to a subject in need thereof in an amount of about 3 mg/kg. In other embodiments, REGN2810 is administered to a subject in need thereof in an amount of about 1 mg/kg. In some embodiments, REGN2810 is administered to a subject in need thereof in an amount of about 200 mg once every two weeks. In some embodiments, REGN2810 is administered to a subject in need thereof in an amount of about 3 mg/kg once every two weeks. In other embodiments, REGN2810 is administered to a subject in need thereof in an amount of about 1 mg/kg once every two weeks.
[0309] In certain embodiments, the PD-1 or PD-L1 inhibitor is atezolizumab and the amount of atezolizumab that is administered is from about 10 mg/day up to, and including, 1200 mg/day. In certain embodiments, the amount of atezolizumab that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of atezolizumab that is administered is from about 100 mg/day to 600 mg/day. In certain embodiments, the amount of atezolizumab that is administered per day is about 10 mg, about 60 mg, about 120 mg, about 180 mg, about 240 mg, about 420 mg or about 560 mg.
[0310] In certain embodiments, the methods described herein further comprise administering atezolizumab at a dosage of 1200 mg/20mL in a single dose. In certain embodiments, atezolizumab is administered at a dosage of 15 mg/kg in a single dose. In some embodiments, atezolizumab is administered at a dosage of 1200 mg as an intravenous infusion. In some embodiments, atezolizumab is administered at a dosage of 1200 mg as an intravenous infusion every 3 weeks. In some embodiments, atezolizumab is administered at a dosage of 1200 mg as an intravenous infusion over 60 minutes every 3 weeks. In another embodiment, the amount of atezolizumab that is administered is about 600 mg, about 900 mg, about 1000 mg, about 1 lOOmg, about 1200 mg, about 1300 mg, about 1500 mg, or about 1800 mg in a single dose.
[0311] In certain embodiments, the PD-1 or PD-Ll inhibitor is avelumab and the amount of avelumab that is administered is from about 10 mg/day up to, and including, 1000 mg/day. In certain embodiments, the amount of avelumab that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of avelumab that is administered is from about 100 mg/day to 600 mg/day. In certain embodiments, the amount of avelumab that is administered per day is about 10 mg, about 50 mg, about 100 mg, about 300 mg, about 500 mg, about 700 mg or about 900 mg.
[0312] In certain embodiments, the methods described herein further comprise administering avelumab at a dosage of 10 mg/kg every two weeks. In some embodiments, 10 mg/kg of avelumab is administered as an intravenous infusion every two weeks. In some embodiments, 10 mg/kg of avelumab is administered as an intravenous infusion over 60 minutes every two weeks. In certain embodiments, avelumab is administered at a dosage of 20 mg/kg every two weeks. In another embodiment, the amount of avelumab that is administered is about 100 mg, 300 mg, 500 mg, 750 mg, 1200 mg or 1500 mg in a every two weeks. In some instances, the patient is premedicated with acetaminophen and/or an antihistamine for the first 4 infusions and subsequently as needed.
[0313] In certain embodiments, the PD-1 or PD-Ll inhibitor is BMS-936559 and the amount of BMS- 936559 that is administered is from about 10 mg/day up to, and including, 1000 mg/day. In certain embodiments, the amount of BMS-936559 that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of BMS-936559 that is administered is from about 100 mg/day to 600 mg/day. In certain embodiments, the amount of BMS-936559 that is administered per day is about 10 mg, about 30 mg, about 80 mg, about 100 mg, about 200 mg, about 300 mg or about 500 mg.
[0314] In certain embodiments, the PD-1 or PD-Ll inhibitor is BMS-936559 and the amount of BMS- 936559 that is administered is 3 mg/kg every two weeks. In certain embodiments, the amount of BMS- 936559 that is administered is 2 mg/kg every two weeks. In another embodiment, the amount of BMS- 936559 that is administered is about 50 mg, 100 mg, 100 mg, 250 mg, 350 mg or 500 mg every two weeks.
[0315] In certain embodiments, the PD-1 or PD-Ll inhibitor is durvalumab and the amount of durvalumab that is administered is from about 10 mg/day up to, and including, 1000 mg/day. In certain embodiments, the amount of durvalumab that is administered is from about 10 mg/day to 600 mg/day. In certain embodiments, the amount of durvalumab that is administered is from about 100 mg/day to 600 mg/day. In certain embodiments, the amount of durvalumab that is administered per day is about 10 mg, about 50 mg, about 100 mg, about 300 mg, about 500 mg, about 700 mg or about 900 mg.
[0316] In certain embodiments, the PD-1 or PD-Ll inhibitor is durvalumab and the amount of durvalumab that is administered is 10 mg/kg every two weeks. In certain embodiments, the amount of durvalumab that is administered is 20 mg/kg every four weeks. In another embodiment, the amount of durvalumab that is administered is about 100 mg, 400 mg, 800 mg, 1200 mg, 1500 mg or 2000 mg in a single dose.
[0317] In certain embodiments, a PD-1 or PD-Ll inhibitor is administered once per day, twice per day, or three times per day. In certain embodiments, the PD-1 or PD-Ll inhibitor is administered once per day.
In certain embodiments, the PD-1 or PD-Ll inhibitor is administered once per day, twice per day, or three times per day. In certain embodiments, the PD-1 or PD-Ll inhibitor is administered once per day. In certain embodiments, the PD-1 or PD-Ll inhibitor is co-administered (e.g., in a single dosage form), once per day.
[0318] In certain embodiments, the PD-1 or PD-Ll inhibitor is administered once a week. In certain embodiments, the PD-1 or PD-Ll inhibitor is administered once every two, three, four or five weeks. In certain embodiments, the PD-1 or PD-Ll inhibitor is administered intravenously or through direct injection. In certain embodiments of the combination therapy described herein, one agent is administered orally and another agent is administered intravenously.
[0319] It will be understood, however, that the specific dose level and frequency of dosage for any particular patient can be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
Additional Combination Therapy
[0320] In certain embodiments, the methods of combination therapy comprising a compound of Formula (I), an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor can also be combined or used in combination with a third agent or therapies useful in the treatment, prevention, or amelioration of one or more symptoms of a proliferative disorders, diseases, or conditions.
[0321] Suitable third agent of therapies include, but are not limited to, ( 1) alpha-adrenergic agents; (2) antiarrhythmic agents; (3) anti-atherosclerotic agents, such as ACAT inhibitors; (4) antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; (5) anticancer agents and cytotoxic agents, e.g., alkylating agents, such as nitrogen mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and triazenes; (6) anticoagulants, such as acenocoumarol, argatroban, bivalirudin, lepirudin, fondaparinux, heparin, phenindione, warfarin, and xirnelagatran, (7) anti-diabetic agents, such as biguanides (e.g., metformin), glucosidase inhibitors (e.g., acarbose), insulins, meglitinides (e.g. , repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiozolidinediones (e.g. , troglitazone, rosiglitazone, and pioglitazone), and PPAR-gamma monists; (8) antifungal agents, such as amorolfine, amphotericin B, anidulafungin, bifonazole, butenafine, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fenticonazole, filipin, fluconazole, isoconazole, itraconazole, ketoconazole, micafungin, miconazole, naftifine, natamycin, nystatin, oxyconazole, ravuconazole, posaconazole, rimocidin, sertaconazole, sulconazole, terbinafine, terconazole, tioconazole, and voriconazole; (9) antiinflammatories, e.g. , non-steroidal anti -inflammatory agents, such as aceclofenac, acemetacin, amoxiprin, aspirin, azapropazone, benorilate, bromfenac, carprofen, celecoxib, choline magnesium salicylate, diclofenac, diflunisal, etodolac, etoricoxib, faislamine, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indometacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, lumiracoxib, meclofenamic acid, mefenamic acid, meloxicam, metamizole, methyl salicylate, magnesium salicylate, nabumetone,
naproxen, nimesulide, oxyphenbutazone, parecoxib, phenylbutazone, piroxicam, salicyl salicylate, sulindac, sulfinpyrazone, suprofen, tenoxicam, tiaprofenic acid, and tolmetin; (10) antimetabolites, such as folate antagonists, purine analogues, and pyrimidine analogues; (11) anti -platelet agents, such as GPIIb/IlIa blockers (e.g., abciximab, eptifibatide, and tirofiban), P2Y(AC) antagonists (e.g., clopidogrel, ticlopidine and CS-747), cilostazol, dipyridamole, and aspirin; (12) antiproliferatives, such as methotrexate, FK506 (tacrolimus), and mycophenolate mofetil; (13) anti-TNF antibodies or soluble TNF receptor, such as etanercept, rapamycin, and leflunimide; (14) aP2 inhibitors; (15) beta-adrenergic agents, such as carvedilol and metoprolol; (16) bile acid secjuestrants, such as questran; (17) calcium channel blockers, such as amlodipine besylate; (18) chemotherapeutic agents; (19) cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; (20) cyclosporins; (21) cytotoxic drugs, such as azathioprine and cyclophosphamide; (22) diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzothiazide, ethacrynic acid, ticrynafen, chlorthalidone, furosenide, muzolimine, bumetanide, triamterene, amiloride, and spironolactone; (23) endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; (24) enzymes, such as L-asparaginase; (25) Factor Vila Inhibitors and Factor Xa Inhibitors; (26) fame syl -protein transferase inhibitors; (27) fibrates; (28) growth factor inhibitors, such as modulators of PDGF activity; (29) growth hormone secretagogues; (30) HMG CoA reductase inhibitors, such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522 (also known as rosuvastatin, atavastatin, or visastatin); neutral endopeptidase (NEP) inhibitors; (31) hormonal agents, such as glucocorticoids (e.g., cortisone), estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone antagonists, and octreotide acetate; (32) immunosuppressants; (33) mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; (34) microtubule-disruptor agents, such as ecteinascidins; (35) microtubule -stabilizing agents, such as pacitaxel, docetaxel, and epothilones A-F; (36) MTP Inhibitors; (37) niacin; (38) phosphodiesterase inhibitors, such as PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors (e.g., sildenafil, tadalafil, and vardenafil); (39) plant-derived products, such as vinca alkaloids, epipodophyllotoxins, and taxanes; (40) platelet activating factor (PAF) antagonists; (41) platinum coordination complexes, such as cisplatin, satraplatin, and carboplatin; (42) potassium channel openers; (43) prenyl -protein transferase inhibitors; (44) protein tyrosine kinase inhibitors; (45) renin inhibitors; (46) squalene synthetase inhibitors; (47) steroids, such as aldosterone, beclometasone, betamethasone, deoxycorticosterone acetate, fludrocortisone, hydrocortisone (Cortisol), prednisolone, prednisone, methylprednisolone, dexamethasone, and triamcinolone; (48) TNF -alpha inhibitors, such as tenidap; (49) thrombin inhibitors, such as hirudin; (50) thrombolytic agents, such as anistreplase, reteplase, tenecteplase, tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase,
prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC); (51) thromboxane receptor antagonists, such as ifetroban; (52) topoisomerase inhibitors; (53) vasopeptidase inhibitors (dual NEP-ACE inhibitors), such as omapatrilat and gemopatrilat, and (54) other miscellaneous agents, such as, hydroxyurea, procarbazine, mitotane, hexamethylmelamine, and gold compounds.
[0322] In certain embodiments, the third therapies that may be used in combination with the methods provided herein include, but are not limited to, surgery, endocrine therapy, biologic response modifiers (e.g., interferons, interleukins, and tumor necrosis factor (TNF)), hyperthermia and cryotherapy, and agents to attenuate any adverse effects (e.g., antiemetics).
[0323] In certain embodiments, the third therapeutic agents that may be used in combination with the compounds provided herein include, but are not limited to, alkylating drugs (mechlorethamine, chlorambucil, cyclophosphamide, melphalan, and ifosfamide), antimetabolites (cytarabine (also known as cytosine arabinoside or Ara-C), and methotrexate), purine antagonists and pyrimidine antagonists (6- mercaptopurine, 5-fluorouracil, cytarbine, and gemcitabine), spindle poisons (vinblastine, vincristine, and vinorelbine), podophyllotoxins (etoposide, irinotecan, and topotecan), antibiotics (daunorubicin, doxorubicin, bleomycin, and mitomycin), nitrosoureas (carmustine and lomustine), enzymes
(asparaginase), and hormones (tamoxifen, leuprolide, flutamide, and megestrol), imatinib, adriamycin, dexamethasone, and cyclophosphamide. For a more comprehensive discussion of updated cancer therapies; See, https://www.nci.nih.gov/, a list of the FDA approved oncology drugs at
https://www.fda.gov/cder/cancer/dniglistframe.htm, and The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby incorporated by reference.
[0324] In another embodiment, methods provided herein comprise administration of a compound of Formula (I), or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor, together with administration of one or more
chemotherapeutic agents and/or therapies selected from: alkylation agents (e.g., cisplatin, carboplatin); antimetabolites (e.g., methotrexate and 5-FU); antitumor antibiotics (e.g., adriamymycin and bleomycin); antitumor vegetable alkaloids (e.g., taxol and etoposide); antitumor hormones (e.g., dexamethasone and tamoxifen); antitumor immunological agents (e.g., interferon α, β, and γ); radiation therapy; and surgery. In certain embodiments, the one or more chemotherapeutic agents and/or therapies are administered to the subject before, during, or after the administration of a compound of Formula (I), or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor.
[0325] Such other agents, or drugs, can be administered, by a route and in an amount commonly used therefor, simultaneously or sequentially with a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor. When a compound of Formula (I) and a PD-1 or PD-L l inhibitor are used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor can be utilized, but is not required. Accordingly, the pharmaceutical compositions provided herein include those that also contain one or more other active ingredients or therapeutic agents, in addition to a compound of Formula (I).
Pharmaceutical Compositions and Routes of Administration
[0326] Provided herein is a pharmaceutical composition comprising a compound of Formula (I), a PD-1 or PD-L1 inhibitor, and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer, or stabilizer. In some embodiments, the compound of Formula (I) and a PD-1 or PD-L 1 inhibitor are present in the same pharmaceutical composition. In some embodiments, the compound of Formula (I) and the PD-1 or PD-L1 inhibitor are in different pharmaceutical compositions.
[0327] In one embodiment, the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers. The pharmaceutical compositions provided herein that are formulated for oral administration may be in tablet, capsule, powder, or liquid form. In some embodiments, a tablet comprises a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol may be included. In some embodiments, a capsule comprises a solid carrier such as gelatin.
[0328] In another embodiment, the pharmaceutical compositions are provided in a dosage form for parenteral administration, which comprise a compound provided herein, and one or more
pharmaceutically acceptable excipients or carriers. Where pharmaceutical compositions may be formulated for intravenous, cutaneous or subcutaneous injection, the active ingredient will be in the form of a parenterally acceptable aqueous solution, which is pyrogen-free and has a suitable pH, isotonicity, and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles, such as Sodium Chloride injection, Ringer's injection, or Lactated Ringer's injection. In some embodiments, preservatives, stabilizers, buffers, antioxidants, and/or other additives are included as required.
[0329] In yet another embodiment, the pharmaceutical compositions are provided in a dosage form for topical administration, which comprise a compound provided herein, and one or more pharmaceutically acceptable excipients or carriers.
[0330] The pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, and programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Delivery Technology, 2nd Edition, Rathbone et al , Eds., Marcel Dekker, Inc.: New York, NY, 2008).
[0331] The pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unites-
dosage form may be administered in fractions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit -dosage form. Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.
[0332] The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the
administration of the formulations.
[0333] In certain embodiments, the pharmaceutical compositions provided herein further comprise one or more chemotherapeutic agents as defined herein.
A. Oral Administration
[0334] The pharmaceutical compositions provided herein for oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye -migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
[0335] Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose,
methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, PA); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The amount of a binder or filler in the pharmaceutical compositions provided herein
varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
[0336] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets. The amount of a diluent in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
[0337] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation -exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.
[0338] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, MD) and CAB-O-SIL® (Cabot Co. of Boston, MA); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.
[0339] Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, MA), and asbestos-free talc. Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water- soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene
sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose,
hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup. Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric and tartaric acid. Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.
[0340] It should be understood that many carriers and excipients may serve several functions, even within the same formulation.
[0341] The pharmaceutical compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film -coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film -coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to,
hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.
[0342] The tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants.
Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.
[0343] The pharmaceutical compositions provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate . The hard gelatin capsule, also known as the dry -filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The
liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.
[0344] The pharmaceutical compositions provided herein for oral administration can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups. An emulsion is a two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil. Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative. Suspensions may include a pharmaceutically acceptable suspending agent and preservative. Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, e.g., acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, and hydroalcoholic solutions. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative. For a liquid dosage form, for example, a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be measured conveniently for administration.
[0345] Other useful liquid and semisolid dosage forms include, but are not limited to, those containing the active ingredient(s) provided herein, and a dialkylated mono- or poly-alkylene glycol, including, 1,2- dimetboxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol -350 -dimethyl ether, polyethylene glycol-550-dimcthyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol. These formulations can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolarnine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium rnetabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
[0346] The pharmaceutical compositions provided herein for oral administration can be also provided in the forms of liposomes, micelles, microspheres, or nanosystems. Mice liar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458.
[0347] The pharmaceutical compositions provided herein for oral administration can be provided as non- effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form.
Pharmaceutically acceptable carriers and excipients used in the non-effervescent granules or powders may include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.
[0348] Coloring and flavoring agents can be used in all of the above dosage forms.
[0349] The pharmaceutical compositions provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
B. Parenteral Administration
[0350] The pharmaceutical compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.
[0351] The pharmaceutical compositions provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, Remington: The Science and Practice of Pharmacy, supra).
[0352] The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water- miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
[0353] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Suitable water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N-methyl-2-pyrrolidone, NN- dimethylacetamide, and dimethyl sulfoxide.
[0354] Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl -and propyl-parabens, and sorbic acid.
Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants are those as described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and
polyvinylpyrrolidone. Suitable emulsifying agents are those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including a-cyclodextrin, β-cyclodextrin, hydroxypropyl- -cyclodextrin, sulfobutylether- -cyclodextrin, and sulfobutylether 7- -cyclodextrin (CAPTISOL®, CyDex, Lenexa, KS).
[0355] When the pharmaceutical compositions provided herein are formulated for multiple dosage administration, the multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungi static concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
[0356] In one embodiment, the pharmaceutical compositions for parenteral administration are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions.
[0357] The pharmaceutical compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
[0358] The pharmaceutical compositions provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.
[0359] Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutyl- methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene -vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and metliacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
[0360] Suitable outer polymeric membranes include but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, buty] rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.
C. Topical Administration
[0361] The pharmaceutical compositions provided herein can be administered topically to the skin, orifices, or mucosa. The topical administration, as used herein, includes (intradermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration.
[0362] The pharmaceutical compositions provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, and dermal patches. The topical formulation of the pharmaceutical compositions provided herein can also comprise liposomes, micelles, microspheres, nanosystems, and mixtures thereof.
[0363] Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations provided herein include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.
[0364] The pharmaceutical compositions can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as
POWDERJECT™ (Chiron Corp., Emeryville, CA), and BIOJECT™ (Bioject Medical Technologies Inc., Tualatin, OR).
[0365] The pharmaceutical compositions provided herein can be provided in the forms of ointments, creams, and gels. Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in -oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid (see, Remington: The Science and Practice of Pharmacy, supra). These vehicles are emollient but generally require addition of antioxidants and preservatives.
[0366] Suitable cream base can be oil-in-water or water-in-oil. Suitable cream vehicles may be water- washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase is also called the "internal" phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. In some embodiments, the emulsifier in a cream formulation is a nonionic, anionic, cationic, or amphoteric surfactant.
[0367] Gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier. Suitable gelling agents include, but are
not limited to, crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, and
CARBOPOL®; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinyl alcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.
[0368] The pharmaceutical compositions provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas. These dosage forms can be manufactured using conventional processes as described in Remington: The Science and Practice of Pharmacy, supra.
[0369] Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient(s) inside the orifices. Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening agents, which produce a melting point in the proximity of body temperature, when formulated with the pharmaceutical compositions provided herein; and antioxidants as described herein, including bisulfite and sodium metabisulfite. Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di- and triglycerides of fatty acids, and hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, and polyacrylic acid;. Combinations of the various vehicles can also be used. Rectal and vaginal suppositories may be prepared by
compressing or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g.
[0370] The pharmaceutical compositions provided herein can be administered ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.
[0371] The pharmaceutical compositions provided herein can be administered intranasally or by inhalation to the respiratory tract. The pharmaceutical compositions can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1,1, 1,2-tetrafluoroethane or 1,1, 1,2,3,3, 3-heptafluoropropane. The pharmaceutical compositions can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops. For intranasal use, the powder can comprise a bioadhesive agent, including chitosan or cyclodextrin.
[0372] Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active ingredient provided herein; a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
[0373] The pharmaceutical compositions provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less. Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
[0374] Capsules, blisters, and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical compositions provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as /-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate. Other suitable excipients or carriers include, but are not limited to, dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose. The pharmaceutical compositions provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol; and/or sweeteners, such as saccharin and saccharin sodium.
[0375] The pharmaceutical compositions provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.
D. Modified Release
[0376] The pharmaceutical compositions provided herein can be formulated as a modified release dosage form. As used herein, the term "modified release" refers to a dosage form in which the rate or place of release of the active ingredient(s) is different from that of an immediate dosage form when administered by the same route. Modified release dosage forms include, but are not limited to, delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. The pharmaceutical compositions in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix controlled release devices, osmotic controlled release devices, multiparticulate controlled release devices, ion-exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof. The release rate of the active ingredient(s) can also be modified by varying the particle sizes and polymorphism of the active ingredient(s).
[0377] Examples of modified release include, but are not limited to, those described in U.S. Pat. Nos. : 3,845,770; 3,916,899; 3,536,809; 3,598, 123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5, 120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739, 108; 5,891,474; 5,922,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6, 1 13,943; 6, 197,350; 6,248,363; 6,264,970; 6,267,981; 6,376,461 ; 6,419,961; 6,589,548; 6,613,358; and 6,699,500.
1. Matrix Controlled Release Devices
[0378] The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated using a matrix controlled release device known to those skilled in the art (see, Takada et al. in "Encyclopedia of Controlled Drug Delivery," Vol. 2, Mathiowitz Ed., Wiley, 1999).
[0379] In certain embodiments, the pharmaceutical compositions provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water-swellable, erodible, or soluble polymers, including, but not limited to, synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
[0380] Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin;
hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; cellulosics, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethyl hydroxyethyl cellulose (EHEC); polyvinyl pyrrolidone;
polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid;
copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT®, Rohm America, Inc., Piscataway, NJ); poly(2 -hydroxyethyl -methacrylate), polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid; and other acrylic acid derivatives, such as homopolymers and copolymers of butylmethacrylate, methyl methacrylate, ethyl methacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and (trimethylaminoethyl)methacrylate chloride.
[0381] In certain embodiments, the pharmaceutical compositions provided herein are formulated with a non-erodible matrix device. The active ingredient(s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once administered. Materials suitable for use as a non-erodible matrix device include, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate,
polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate -methyl methacrylate copolymers, ethylene -vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubbers, epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, ethylene/vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubbers, polydimethylsiloxanes, and silicone carbonate copolymers; hydrophilic polymers, such as ethyl cellulose, cellulose acetate, crospovidone, and cross-linked partially hydrolyzed polyvinyl acetate; and fatty compounds, such as carnauba wax, microcrystalline wax, and triglycerides.
[0382] In a matrix controlled release system, the desired release kinetics can be controlled, for example, via the polymer type employed, the polymer viscosity, the particle sizes of the polymer and/or the active ingredient(s), the ratio of the active ingredient(s) versus the polymer, and other excipients or carriers in the compositions.
[0383] The pharmaceutical compositions provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, and melt-granulation followed by compression.
2. Osmotic Controlled Release Devices
[0384] The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including, but not limited to, one-chamber system, two-chamber system, asymmetric membrane technology (AMT), and extruding core system (ECS). In general, such devices have at least two components: (a) a core which contains an active ingredient; and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core. The semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port(s).
[0385] In addition to the active ingredient(s), the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device. One class of osmotic agents is water-swellable hydrophilic polymers, which are also referred to as "osmopolymers" and "hydrogels." Suitable water-swellable hydrophilic polymers as osmotic agents include, but are not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly(2 -hydroxy ethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid,
polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers,
PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC) and carboxyethyl, cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.
[0386] The other class of osmotic agents is osmogens, which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol; organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and mixtures thereof.
[0387] Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient(s) is initially delivered from the dosage form. For example, amorphous sugars, such as MAN OGEM EZ (SPI Pharma, Lewes, DE) can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an
extended period of time. In this case, the active ingredient(s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.
[0388] The core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.
[0389] Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water- insoluble at physiologically relevant pHs, or are susceptible to being rendered water-insoluble by chemical alteration, such as crosslinking. Examples of suitable polymers useful in forming the coating, include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p- toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene -vinyl acetate, EC, PEG, PPG, PEG/PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly-(methacrylic) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan, collagen, gelatin, polyalkenes, polyethers, polysulfones,
polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
[0390] Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798, 1 19. Such hydrophobic but water-vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes
[0391] The delivery port(s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220.
[0392] The total amount of the active ingredient(s) released and the release rate can substantially by modulated via the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports
[0393] The pharmaceutical compositions in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.
[0394] The osmotic controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: The Science and Practice of Pharmacy, supra; Santus and Baker, J. Controlled Release 1995, 35, 1-21 ; Verma et al., Drug Development and Industrial Pharmacy 2000, 26, 695-708; Verma et al., J. Controlled Release 2002, 79, 7-27).
[0395] In certain embodiments, the pharmaceutical compositions provided herein are formulated as AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient(s) and other pharmaceutically acceptable excipients or carriers. See, U.S. Pat. No. 5,612,059 and WO 2002/17918. The AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.
[0396] In certain embodiments, the pharmaceutical compositions provided herein are formulated as ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient(s), a hydroxylethyl cellulose, and other pharmaceutically acceptable excipients or carriers.
3. Multiparticulate Controlled Release Devices
[0397] The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a multiplicity of particles, granules, or pellets, ranging from about 10 μπι to about 3 mm, about 50 μπι to about 2.5 mm, or from about 100 μπι to about 1 mm in diameter. Such multiparticulates can be made by the processes known to those skilled in the art, including wet-and dry-granulation, extrusion spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores. See, for example, Multiparticulate Oral Drug Delivery; Marcel Dekker: 1994; and Pharmaceutical Pelletization Technology; Marcel Dekker: 1989.
[0398] Other excipients or carriers as described herein can be blended with the pharmaceutical compositions to aid in processing and forming the multiparticulates. The resulting particles can themselves constitute the multiparticulate device or can be coated by various film-forming materials, such as enteric polymers, water-swellable, and water-soluble polymers. The multiparticulates can be further processed as a capsule or a tablet.
4. Targeted Delivery
[0399] The pharmaceutical compositions provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated, including liposome-, resealed erythrocyte-, and antibody-based delivery systems. Examples include, but are not limited to, those disclosed in U.S. Pat. Nos. 6,316,652; 6,274,552; 6,271,359; 6,253,872; 6, 139,865; 6, 131,570; 6, 120,751 ; 6,071,495; 6,060,082; 6,048,736; 6,039,975; 6,004,534; 5,985,307; 5,972,366; 5,900,252; 5,840,674; 5,759,542; and 5,709,874.
Articles of Manufacture
[0400] The compounds provided herein can also be provided as an article of manufacture using packaging materials well known to those of skill in the art. See, e.g. , U.S. Pat. Nos. 5,323,907; 5,052,558; and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister
packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
[0401] Provided herein also are kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a subject. In certain embodiments, the kit provided herein includes one or more containers and a dosage form of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and a PD-1 or PD-Ll inhibitor.
[0402] In certain embodiments, the kit provided herein includes one or more containers and a dosage form of a compound of Formula (I), or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof and PD-1 or PD-Ll inhibitor. Kits provided herein can further include devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, needle-less injectors drip bags, patches, and inhalers.
[0403] Kits provided herein can further include pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate -free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: aqueous vehicles, including, but not limited to, Water for Injection USP, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles, including, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles, including, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
[0404] The disclosure will be further understood by the following non-limiting examples.
[0405] Additional Embodiments
[0406] Embodiments include embodiment PI to P31 following.
[0407] Embodiment P 1. A method for treating or preventing a disease comprising administering:
(i) an effective amount of a compound of Formula (I);
Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or Ci_6 alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or
C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_6 alkyl, C2_¾ alkenyl, C2_¾ alkynyl, C3-10 cycloalkyl, C(,-u aryl, C7_15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, - C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, - OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, - NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, - NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)„-(C6_14 aryl) or -(CR5fR5g)„-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -
NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, Rx, Rla, Rlb, Rlc, Rld, R5a, R5b, R5c, R5d, R5e, R5f, and R5g is optionally substituted with one, two, three, four, or five substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; and (c) - C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, and -S(0)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one, two, three, or four substituents Qa;
wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl; and (c) -C(0)Re, -C(0)ORe, -C(0)NRfRg, -C(NRe)NRfRg, -ORe, - OC(0)Re, -OC(0)ORe, -OC(0)NRfRg, -OC(=NRe)NRfRg, -OS(0)Re, -OS(0)2Re, -OS(0)NRfRg, - OS(0)2NRfRg, -NRfRg, -NReC(0)Rh, -NReC(0)ORh, -NReC(0)NRfRg, -NReC(=NRh)NRfRg, - NReS(0)Rh, -NReS(0)2Rh, -NReS(0)NRfRg, -NReS(0)2NRfRg, -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg, and -S(0)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl; or
wherein two substituents Q that are adjacent to each other optionally form a C3_io cycloalkenyl, C6_i aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa; and
(ii) an effective amount of a PD-1 or PD-L1 inhibitor, wherein the disease is cancer.
[0408] Embodiment P2. The method of embodiment PI, wherein R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, or heteroaryl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -
OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -S(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, - NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc.
[0409] Embodiment P3. The method of embodiment PI, wherein R5a and R5b are each independently (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, - OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, - OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -
NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc.
[0410] Embodiment P4. The method of embodiment P3, wherein R5a and R5b are each methyl, optionally substituted with one, two, or three halo(s).
[0411] Embodiment P5. The method of any one of embodiments P1-P4, wherein n is 1.
[0412] Embodiment P6. The method of any one of embodiments P1-P5, wherein R5f and R5g are each hydrogen.
[0413] Embodiment P7. The method of any one of embodiments P1-P4, wherein n is 0.
[0414] Embodiment P8. The method of any one of embodiments P1-P7, wherein m is 0.
[0415] Embodiment P9. The method of any one of embodiments P1-P8, wherein the compound of Formula (I) is of Formula (XI):
Formula (XI),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R a, R , R c, R , and R e are each independently (a) hydrogen, cyano, halo, or nitro; (b)
Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6.u aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; or (c) -C(0)Ra, - C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, or -S(0)2NRbRc; or
two of R a, R , R c, R , and R e that are adjacent to each other form C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa.
[0416] Embodiment P I 0. The method of any one of embodiments P1-P9, wherein the compound of Formula (I) is Compound I:
Compound I,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0417] Embodiment P 1 1. The method of any one of embodiments P1-P10, wherein the PD-1 or PD-Ll inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, BGB-A317, PDR001 , REGN2810, or durvalumab, or a variant or biosimilar thereof, or combinations thereof.
[0418] Embodiment P 12. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is pidilizumab, or a variant or biosimilar thereof.
[0419] Embodiment P 13. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is nivolumab, or a variant or biosimilar thereof.
[0420] Embodiment P 14. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is pembrolizumab, or a variant or biosimilar thereof.
[0421] Embodiment P 15. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is atezolizumab, or a variant or biosimilar thereof.
[0422] Embodiment P I 6. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is BMS- 936559, or a variant or biosimilar thereof.
[0423] Embodiment P I 7. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is durvalumab, or a variant or biosimilar thereof.
[0424] Embodiment P I 8. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is BGB- A317, or a variant or biosimilar thereof.
[0425] Embodiment P I 9. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is PDR001, or a variant or biosimilar thereof.
[0426] Embodiment P20. The method of embodiment PI 1, wherein the PD-1 or PD-Ll inhibitor is REGN2810, or a variant or biosimilar thereof.
[0427] Embodiment P21. The method of any one of embodiments P1-P20, wherein the cancer is non- Hodgkin's lymphoma, non-small cell lung cancer, melanoma, renal cell cancer, head and neck cancer, colon cancer, or mesothelioma.
[0428] Embodiment P22. The method of any one of embodiments P1-P21, wherein the cancer is melanoma.
[0429] Embodiment P23. The method of any one of embodiments P1-P22, wherein the administration of compounds occurs in one or more cycles.
[0430] Embodiment P24. A method for multiple cycle chemotherapy in a subject, wherein the method comprises administering to the subject at least two chemotherapy cycles, wherein in each chemotherapy cycle, a PI3K inhibitor and a PD-1 or PD-L1 inhibitor is administered to the subject.
[0431] Embodiment P25. The method of embodiment 24, wherein the compounds are administered within 6 hours or less of each other.
[0432] Embodiment P26. The method of either of embodiments P24 or P25, wherein the compounds are administered within 1 hour or less of each other.
[0433] Embodiment P27. The method of any one of embodiments P24-P26, wherein the compounds are administered simultaneously.
[0434] Embodiment P28. The method of any one of embodiments P24-P26, wherein the compounds are administered sequentially.
[0435] Embodiment P29. The method of any one of embodiments P24-P28, wherein the PI3K inhibitor is administered orally and the PD-1 or PD-L1 inhibitor is administered by injection.
[0436] Embodiment P30. The method of any one of embodiments P24-P29, wherein the administration of the second cycle is within 50 days.
[0437] Embodiment P31. The method of any one of embodiments P24-P29, wherein the administration of any additional cycle is within 50 days of the previous cycle.
[0438] Further embodiments include embodiments 1 to 42 following.
[0439] Embodiment 1. A method for treating or preventing cancer, comprising administering:
(i) an effective amount of a compound of Formula (I);
Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or Ci_6 alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or
C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_6 alkyl, C2_¾ alkenyl, C2_¾ alkynyl, C3-10 cycloalkyl, C(,-u aryl, C7_15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, - C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, - OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, - NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, - NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, - ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)„-(C6_14 aryl) or -(CR5fR5g)„-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -
NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, Rx, Rla, Rlb, Rlc, Rld, R5a, R5b, R5c, R5d, R5e, R5f, and R5g is optionally substituted with one, two, three, four, or five substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; and (c) - C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, and -S(0)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one, two, three, or four substituents Qa;
wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl; and (c) -C(0)Re, -C(0)ORe, -C(0)NRfRg, -C(NRe)NRfRg, -ORe, - OC(0)Re, -OC(0)ORe, -OC(0)NRfRg, -OC(=NRe)NRfRg, -OS(0)Re, -OS(0)2Re, -OS(0)NRfRg, - OS(0)2NRfRg, -NRfRg, -NReC(0)Rh, -NReC(0)ORh, -NReC(0)NRfRg, -NReC(=NRh)NRfRg, - NReS(0)Rh, -NReS(0)2Rh, -NReS(0)NRfRg, -NReS(0)2NRfRg, -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg, and -S(0)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl; or
wherein two substituents Q that are adjacent to each other optionally form a C3_io cycloalkenyl, C6_i aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa; and
(ii) an effective amount of a PD-1 or PD-L1 inhibitor.
[0440] Embodiment 2. The method of embodiment 1, wherein R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, or heteroaryl; or (c) -C(0)Rla, -C(0)ORla, - C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -
OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -S(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, - NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc.
[0441] Embodiment 3. The method of embodiment 1, wherein R5a and R5b are each independently (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, - OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, - OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -
NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc.
[0442] Embodiment 4. The method of embodiment 3, wherein R5a and R5b are each methyl, optionally substituted with one, two, or three halo(s).
[0443] Embodiment 5. The method of any one of embodiments 1-4, wherein n is 1.
[0444] Embodiment 6. The method of any one of embodiments 1-5, wherein R5f and R5g are each hydrogen.
[0445] Embodiment 7. The method of any one of embodiments 1-4, wherein n is 0.
[0446] Embodiment 8. The method of any one of embodiments 1-7, wherein m is 0.
[0447] Embodiment 9. The method of any one of embodiments 1-6 or 8, wherein the compound of
Formula (I) is of Formula (XI):
Formula (XI),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R a, R , R c, R , and R e are each independently (a) hydrogen, cyano, halo, or nitro; (b)
Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6.u aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; or (c) -C(0)Ra, - C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, or -S(0)2NRbRc; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa.
[0448] Embodiment 10. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound I:
Compound I,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0449] Embodiment 11. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound II:
Compound II,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0450] Embodiment 12. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound III:
Compound III,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0451] Embodiment 13. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound IV:
Compound IV,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0452] Embodiment 14. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound V:
Compound V,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0453] Embodiment 15. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound VI:
Compound VI,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0454] Embodiment 16. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound VII:
Compound VII,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0455] Embodiment 17. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound VIII:
Compound VIII,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0456] Embodiment 18. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound IX:
Compound IX,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0457] Embodiment 19. The method of any one of embodiments 1-9, wherein the compound of Formula (I) is Compound X:
Compound X,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0458] Embodiment 20. The method of any one of embodiments 1-19, wherein the PD-1 or PD-Ll inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, BGB-A317, PDR001 , REGN2810, or durvalumab, or a variant or biosimilar thereof, or combinations thereof.
[0459] Embodiment 21. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is pidilizumab, or a variant or biosimilar thereof.
[0460] Embodiment 22. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is nivolumab, or a variant or biosimilar thereof.
[0461] Embodiment 23. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is pembrolizumab, or a variant or biosimilar thereof.
[0462] Embodiment 24. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is atezolizumab, or a variant or biosimilar thereof.
[0463] Embodiment 25. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is BMS- 936559, or a variant or biosimilar thereof.
[0464] Embodiment 26. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is durvalumab, or a variant or biosimilar thereof.
[0465] Embodiment 27. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is BGB- A317, or a variant or biosimilar thereof.
[0466] Embodiment 28. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is PDR001, or a variant or biosimilar thereof.
[0467] Embodiment 29. The method of embodiment 20, wherein the PD-1 or PD-Ll inhibitor is REGN2810, or a variant or biosimilar thereof.
[0468] Embodiment 30. The method of any one of embodiments 1-29, wherein the cancer is non- Hodgkin's lymphoma, non-small cell lung cancer, melanoma, renal cell cancer, head and neck cancer, colon cancer, or mesothelioma.
[0469] Embodiment 31. The method of any one of embodiments 1-30, wherein the cancer is melanoma.
[0470] Embodiment 32. The method of any one of embodiments 1-31, wherein the administration of compounds occurs in one or more cycles.
[0471] Embodiment 33. A method for multiple cycle chemotherapy in a subject, wherein the method comprises administering to the subject at least two chemotherapy cycles, wherein in each chemotherapy cycle, a PI3K inhibitor and a PD-1 or PD-L1 inhibitor are administered to the subject.
[0472] Embodiment 34. The method of embodiment 33, wherein the compounds are administered within 6 hours or less of each other.
[0473] Embodiment 35. The method of either of embodiments 33 or 34, wherein the compounds are administered within 1 hour or less of each other.
[0474] Embodiment 36. The method of any one of embodiments 33-35, wherein the compounds are administered simultaneously.
[0475] Embodiment 37. The method of any one of embodiments 33-35, wherein the compounds are administered sequentially.
[0476] Embodiment 38. The method of any one of embodiments 33-35 or 37, wherein the PI3K inhibitor is administered before the PD-1 or PD-L1 inhibitor.
[0477] Embodiment 39. The method of of any one of embodiments 33-35 or 37, wherein the PI3K inhibitor is administered after the PD-1 or PD-L1 inhibitor.
[0478] Embodiment 40. The method of any one of embodiments 33-39, wherein the PI3K inhibitor is administered orally and the PD-1 or PD-L1 inhibitor is administered by injection.
[0479] Embodiment 41. The method of any one of embodiments 33-40, wherein the administration of a second cycle is within 50 days of completion of a first cycle.
[0480] Embodiment 42. The method of any one of embodiments 33-40, wherein the administration of any additional cycle is within 50 days of completion of a previous cycle.
EXAMPLES
[0481] As used herein, the symbols and conventions used in these processes, schemes and examples, regardless of whether a particular abbreviation is specifically defined, are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Specifically, but without limitation, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); mL (milliliters); μί, (microliters); M (molar); mM (millimolar), μΜ (micro molar); eq. (equivalent); mmol (millimoles), Hz (Hertz), MHz (megahertz); hr or hrs (hour or hours); min (minutes); and MS (mass spectrometry).
[0482] For all of the following examples, standard work-up and purification methods known to those skilled in the art can be utilized. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions conducted at room temperature unless otherwise noted. Synthetic
methodologies illustrated herein are intended to exemplify the applicable chemistry through the use of specific examples and are not indicative of the scope of the disclosure.
[0483] Synthesis of Compound I is described in US Patent No. 9,056,852 B2, which is incorporated by reference for such disclosure.
Example 1 : Synthesis of 4-(2-(difluoromethyl)-lH-benzo[^imidazol-l-yl)-N-(2-methyl-l-(2-(l- methylpiperidin-4-yl)phenyl)propan-2-yl)-6-morpholino-l,3,5-triazin-2-amine, Compound I
[0484] A mixture of 4-(2-(difluoromethyl)-lH-benzo[d]imidazol-l-yl)-N-(2-methyl-l -(2-(piperidin-4- yl)phenyl)propan-2-yl)-6-moφholino-l,3,5-triazin-2 -amine (80 mg, 0.14 mmol), aq. formaldehyde (37%, 23 mg), and sodium cyanoborohydride ( 11 mg, 0.17 mmol) in methanol (2 mL) was stirred at room temperature for 1 hr. The crude product was purified by prep-HPLC to give compound 1 (1 1 mg, 13% yield) as a white solid: 99% purity (HPLC); MS m/z: 577.3 (M+1); ¾ NMR (CDC13, 500 MHz) δ 8.37 (d, 1H), 7.90 (d, 1H), 7.64 (t, 1H), 7.42 (m, 2H), 7.32 (d, 1H), 7.24 (1, 1H), 7.13 (t, 1H), 7.07 (d, 1H), 5.15 (s, 1H), 4.00-3.70 (m, 8H), 3.28 (s, 2H), 2.94 (m, 2H), 2.78 (m, 2H), 2.28 (s, 3H), 1.891.60 (m, 6H), 1.53 (s, 6H) ppm.
Example 2: MC38 Murine Colon Carcinoma Model for Combination of PI3K inhibitor and PD-1 inhibitor
[0485] The combination of a PI3K inhibitor (Compound I) and a PD-1 inhibitor (RPM1-14) was evaluated utilizing a MC38 murine colon carcinoma syngeneic model in female immunocompetent C57BL/6 mice. The study was designed to plot the survival time of murine specimens when treated with the combination of Compound I and the PD-1 inhibitor.
[0486] Compound I dosing solutions were prepared weekly. Formulations of Compound I were prepared by adding the appropriate amount of 20% VE-TPGS, 80% 100 mM citrate buffer, pH 3.5 solution (vehicle) to Compound I. The resulting suspension was stirred overnight to yield a 5 mg/mL dose solution. This solution provided a dosage of 50 mg/kg in a dosing volume of 10 mL/kg. The Compound I dosing solution was stored at 4 °C when not in use.
[0487] The PD-1 inhibitor (anti-PD-1 antibody Clone RMP1-14, Lot No. 5792-599016J1) was purchased by CR Discovery Services from Bio X Cell and stored at 4 °C upon receipt. Anti-PD-1 antibody dosing solutions were prepared by diluting aliquots of the stock (6.37 mg/mL) to 0.5 mg/mL in sterile PBS, yielding a dosage of 100 μg/animal in a fixed dosing volume of 0.2 mL/animal.
[0488] Tumors were measured twice weekly. Treatment response was to be evaluated from tumor growth delay (TGD), the increase in median time-to-endpoint (TTE) in treated versus control mice, and from comparison of survival curves using logrank analysis. Each animal was marked for tumor progression when its tumor reached the 1000 mm3 volume endpoint, and any animal that did not reach the endpoint was euthanized at the end of the study and assigned a TTE value equal to the last day of the study (Day 45).
[0489] The median TTE for control Group 1 was 19.0 days, establishing a maximum TGD of 137% for this study. All treatments evaluated in the study were acceptably-tolerated, with acceptable mean BW losses and no treatment-related (TR) deaths.
Tumor Growth Delay (TGD) Analysis
[0490] Animals were monitored individually for tumor growth until Day 45. The study protocol specified a tumor growth delay assay based on the median time to endpoint (TTE) in a treated group versus the
control group. Each animal was marked for tumor progression (TP) when its tumor reached the 1000 mm3 volume endpoint. The TTE for each mouse was calculated with the following equation:
log10 (endpoint volume) - b where b is the intercept and m is the slope of the line obtained by linear regression of a log -transformed tumor growth data set. The data set is comprised of the first observation that exceeded the study endpoint volume and the three consecutive observations that immediately preceded the attainment of the endpoint volume. Any animal that did not reach endpoint was euthanized at the end of the study and assigned a TTE value equal to the last day of the study (Day 45). In instances in which the log -transformed calculated TTE preceded the day prior to reaching endpoint or exceeded the day of reaching tumor volume endpoint, a linear interpolation was performed to approximate TTE.
[0491] On Day 45, MTV (n) was defined as the median tumor volume of the number of animals, n, that survived to the last day and whose tumors had not reached the volume endpoint. Any animal determined to have died from TR causes was to be assigned a TTE value equal to the day of death. Any animal that died from NTR causes was to be excluded from the analysis. Treatment outcome was evaluated from TGD, which was defined as the increase in the median TTE for a treatment group compared to the control group:
TGD = T - C expressed in days, or as a percentage of the median TTE of the control group:
T - C
% TGD = x 100
C where
T = median TTE for a treatment group,
C = median TTE for the control group.
[0492] Survival was analyzed by the Kaplan-Meier method. The logrank (Mantel-Cox) and Gehan- Breslow-Wilcoxon tests determined the significance of the difference between the overall survival experiences (survival curves) of two groups, based on TTE values. A scatter plot was constructed to show TTE values for individual mice, by group. Group median tumor volumes were plotted as functions of time. When an animal exited the study because of tumor size, the final tumor volume recorded for the animal was included with the data used to calculate the median volume at subsequent time points. A Kaplan- Meier plot was constructed to show the percentage of animals in each group remaining on study versus time.
Example 2a
[0493] On Day 1 of the study, four groups of C57BL/6 mice (n = 10 for control group and PD-1 monotherapy; n = 20 for combination therapy) began dosing. Compound I was administered by oral gavage (p.o.) at a dosage of 50 mg/kg in a dosing volume of 10 mL/kg and was adjusted according to the most recent body weight measurement. The PD-1 inhibitor was administered intraperitoneally (i.p.) at a dosage of 100 μg/animal in a fixed dosing volume of 0.2 mL/animal.
[0494] Group 1 was left untreated and served as the control group for the %TGD.
[0495] Group 2 was treated with the PD-1 inhibitor i.p. at a dosage of 100 μg/animal twice weekly for two weeks.
[0496] Group 3 received Compound I p.o. at 50 mg/kg qd x 7 starting on Day 1. Beginning on Day 8, this group was then treated with the PD-1 inhibitor i.p. at 100 μg/animal biwk x 2.
[0497] Group 4 received Compound I p.o. at 50 mg/kg qd x 7 starting on Day 1. Beginning on Day 8, this group was treated with the PD-1 inhibitor i.p. at 100 μg/animal biwk x 2 with the final dose occurring on Day 18. On Day 22, treatment with Compound I resumed at 50 mg/kg once daily for five days (qd x 5, start Day 22).
[0498] Group 5 received Compound I p.o. at 50 mg/kg qd x 7 starting on Day 1. On Day 8, these animals received the PD-1 inhibitor i.p. at 100 μg/animal biwk x 2 with the final dose occurring on Day 18. A second course of the PD-1 inhibitor was administered biwk x 2 beginning on Day 27.
[0499] Group 6 received Compound I p.o. at 50 mg/kg qd x 7 starting on Day 1. On Day 8, these animals received the PD-1 inhibitor i.p. at 100 μg/animal biwk x 2 with the final dose occurring on Day 18. On Day 22, treatment with Compound I resumed at 50 mg/kg qd x 5. A second course of the PD-1 inhibitor was administered biwk x 2 beginning on Day 27.
[0500] Treatment with Compound I and the PD-1 inhibitor was well-tolerated. All of the Compound I / PD-1 inhibitor combinations provided statistically significant survival benefits. Combination regimens that administered Compound I and the PD-1 inhibitor in two chemotherapy cycles were more effective than one chemotherapy cycle (Group 6 vs Group 3) and more effective than a single cycle of the PD-1 inhibitor (Group 6 vs Group 2). The results are depicted in Figure 1.
[0501] Combination regimens that administered Compound I and the PD-1 inhibitor in two
chemotherapy cycles were more effective than the administration of one combination cycle and one Compound I cycle (Group 6 vs Group 4) and more effective than the administration of a single cycle of a combination treatment with Compound I and the PD-1 inhibitor. (Group 6 vs Group 3). The results are depicted in Figure 2.
[0502] Combination regimens that administered Compound I and the PD-1 inhibitor in two
chemotherapy cycles were more effective than the administration one combination cycle and one PD-1 inhibitor cycle (Group 6 vs Group 5) and more effective than the administration of a single cycle of a combination treatment with Compound I and the PD-1 inhibitor. (Group 6 vs Group 3). The results are depicted in Figure 3.
Claims (42)
1. A method for treating or preventing cancer, comprising administering:
(i) an effective amount of a compound of Formula (I);
Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
X, Y, and Z are each independently N or CRX, with the proviso that at least two of X, Y, and Z are nitrogen atoms; where Rx is hydrogen or Ci_6 alkyl;
R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc; wherein each Rla, Rlb, Rlc, and Rld is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rlb and Rlc together with the N atom to which they are attached form heterocyclyl;
R3 and R4 are each independently hydrog en or Ci_6 alkyl; or R3 and R4 are linked together to form a bond, Ci_6 alkylene, Ci_6 heteroalkylene, C2_6 alkenylene, or
C2_6 heteroalkenylene;
R5a is (a) hydro gen or halo; (b) Ci_¾ alkyl, C2_¾ alkenyl, C2_¾ alkynyl, C3_io cycloalkyl, C¾_i4 aryl, C7_15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, - C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, - OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, - NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, - NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -
ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, - OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, - NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, - S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc;
R5c is -(CR5fR5g)n-(C6_14 aryl) or -(CR5fR5g)n-heteroaryl;
R5d and R5e are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc;
R5f and R5g are each independently (a) hydrogen or halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, - OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, -NRlbRlc, - NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc; or - S(0)2NRlbRlc; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3_io cycloalkyl or heterocyclyl;
R6 is hydrogen, Ci_6 alkyl, -S-Ci_6 alkyl, -S(0)-Ci_6 alkyl, or -S02-Ci_6 alkyl;
m is 0 or 1 ; and
n is 0, 1, 2, 3, or 4;
wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, Rx, Rla, Rlb, Rlc, Rld, R5a, R5b, R5c, R5d, R5e, R5f, and R5g is optionally substituted with one, two, three, four, or five substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; and (c) - C(0)Ra, -C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, and -S(0)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one, two, three, or four substituents Qa;
wherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, and heterocyclyl; and (c) -C(0)Re, -C(0)ORe, -C(0)NRfRg, -C(NRe)NRfRg, -ORe, - OC(0)Re, -OC(0)ORe, -OC(0)NRfRg, -OC(=NRe)NRfRg, -OS(0)Re, -OS(0)2Re, -OS(0)NRfRg, - OS(0)2NRfRg, -NRfRg, -NReC(0)Rh, -NReC(0)ORh, -NReC(0)NRfRg, -NReC(=NRh)NRfRg, - NReS(0)Rh, -NReS(0)2Rh, -NReS(0)NRfRg, -NReS(0)2NRfRg, -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg, and -S(0)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl; or
wherein two substituents Q that are adjacent to each other optionally form a C3-10 cycloalkenyl, C6_i aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa;
and
(ii) an effective amount of a PD-1 or PD-L1 inhibitor.
2. The method of claim 1, wherein R5b is (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_14 aryl, C7_15 aralkyl, or heteroaryl; or (c) -C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, - C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, -OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, - OS(0)2Rla, -OS(0)NRlbRlc, -S(0)2NRlbRlc, -NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, - NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, -NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, - NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or -S(0)2NRlbRlc.
3. The method of claim 1, wherein R5a and R5b are each independently (a) halo; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl; or (c) - C(0)Rla, -C(0)ORla, -C(0)NRlbRlc, -C(NRla)NRlbRlc, -ORla, -OC(0)Rla, -OC(0)ORla, - OC(0)NRlbRlc, -OC(=NRla)NRlbRlc, -OS(0)Rla, -OS(0)2Rla, -OS(0)NRlbRlc, -OS(0)2NRlbRlc, - NRlbRlc, -NRlaC(0)Rld, -NRlaC(0)ORld, -NRlaC(0)NRlbRlc, -NRlaC(=NRld)NRlbRlc, -NRlaS(0)Rld, - NRlaS(0)2Rld, -NRlaS(0)NRlbRlc, -NRlaS(0)2NRlbRlc, -SRla, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc, or - S(0)2NRlbRlc.
4. The method of claim 3, wherein R5a and R5b are each methyl, optionally substituted with one, two, or three halo(s).
5. The method of claim 1, wherein n is 1.
6. The method of claim 1, wherein R5f and R5g are each hydrogen.
7. The method of claim 1, wherein n is 0.
8. The method of claim 1, wherein m is 0.
9. The method of claim 1, wherein the compound of Formula (I) is of Formula (XI):
Formula (XI),
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:
R7a, R^, R7c, R7d, and R7e are each independently (a) hydrogen, cyano, halo, or nitro; (b) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3_i0 cycloalkyl, C6_i4 aryl, C7_i5 aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Qa; or (c) -C(0)Ra, - C(0)ORa, -C(0)NRbRc, -C(NRa)NRbRc, -ORa, -OC(0)Ra, -OC(0)ORa, -OC(0)NRbRc, - OC(=NRa)NRbRc, -OS(0)Ra, -OS(0)2Ra, -OS(0)NRbRc, -OS(0)2NRbRc, -NRbRc, -NRaC(0)Rd, - NRaC(0)ORd, -NRaC(0)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(0)Rd, -NRaS(0)2Rd, -NRaS(0)NRbRc, - NRaS(0)2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc, or -S(0)2NRbRc; or
two of R7a, R7b, R7c, R7d, and R7e that are adjacent to each other form C3_i0 cycloalkenyl, C6_i4 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Qa.
10. The method of claim 1, wherein the compound of Formula (I) is Compound I:
Compound I,
or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
11. The method of claim 1, wherein the compound of Formula (I) is Compound II:
Compound II,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
12. The method of claim 1, a (I) is Compound III:
Compound III,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
13. The method of claim 1, wherein the compound of Formula (I) is Compound IV:
Compound IV,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
14. The method of claim 1, wherein the compound of Formula (I) is Compound V:
Compound V,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
15. The method of claim 1, wherein the compound of Formula (I) is Compound VI:
Compound VI,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
16. The method of claim 1, a (I) is Compound VII:
Compound VII,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
17. The method of claim 1, wherein the compound of Formula (I) is Compound VIII:
Compound VIII,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
18. The method of claim 1, wherein the compound of Formula (I) is Compound IX:
Compound IX,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
19. The method of claim 1, wherein the compound of Formula (I) is Compound X:
Compound X,
or an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
20. The method of claim 1, wherein the PD-1 or PD-Ll inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, BGB-A317, PDROOl, REGN2810, or durvalumab, or a variant or biosimilar thereof, or combinations thereof.
21. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is pidilizumab, or a variant or biosimilar thereof.
22. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is nivolumab, or a variant or biosimilar thereof.
23. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is pembrolizumab, or a variant or biosimilar thereof.
24. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is atezolizumab, or a variant or biosimilar thereof.
25. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is BMS-936559, or a variant or biosimilar thereof.
26. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is durvalumab, or a variant or biosimilar thereof.
27. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is BGB-A317, or a variant or biosimilar thereof.
28. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is PDR001, or a variant or biosimilar thereof.
29. The method of claim 20, wherein the PD-1 or PD-Ll inhibitor is REGN2810, or a variant or biosimilar thereof.
30. The method of claim 1, wherein the cancer is non-Hodgkin's lymphoma, non-small cell lung cancer, melanoma, renal cell cancer, head and neck cancer, colon cancer, or mesothelioma.
31. The method of claim 1, wherein the cancer is melanoma.
32. The method of claim 1, wherein the administration of compounds occurs in one or more cycles.
33. A method for multiple cycle chemotherapy in a subject, wherein the method comprises administering to the subject at least two chemotherapy cycles, wherein in each chemotherapy cycle, a PI3K inhibitor and a PD-1 or PD-Ll inhibitor are administered to the subject.
34. The method of claim 33, wherein the compounds are administered within 6 hours or less of each other.
35. The method of claim 33, wherein the compounds are administered within 1 hour or less of each other.
36. The method of claim 33, wherein the compounds are administered simultaneously.
37. The method of claim 33, wherein the compounds are administered sequentially.
38. The method of claim 33, wherein the PI3K inhibitor is administered before the PD-1 or PD-Ll inhibitor.
39. The method of claim 33, wherein the PI3K inhibitor is administered after the PD-1 or PD- Ll inhibitor.
40. The method of claim 33, wherein the PI3K inhibitor is administered orally and the PD-1 or PD-Ll inhibitor is administered by injection.
41. The method of claim 24, wherein the administration of a second cycle is within 50 days of completion of a first cycle.
42. The method of claim 24, wherein the administration of any additional cycle is within 50 days of completion of a previous cycle.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510204P | 2017-05-23 | 2017-05-23 | |
| US62/510,204 | 2017-05-23 | ||
| US201762518359P | 2017-06-12 | 2017-06-12 | |
| US62/518,359 | 2017-06-12 | ||
| PCT/US2018/033936 WO2018217787A1 (en) | 2017-05-23 | 2018-05-22 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018271862A1 AU2018271862A1 (en) | 2019-12-12 |
| AU2018271862B2 true AU2018271862B2 (en) | 2022-12-15 |
Family
ID=64395925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018271862A Active AU2018271862B2 (en) | 2017-05-23 | 2018-05-22 | Combination therapy |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11304953B2 (en) |
| EP (1) | EP3630118A4 (en) |
| JP (3) | JP2020521739A (en) |
| KR (2) | KR20240097982A (en) |
| CN (2) | CN110996959A (en) |
| AU (1) | AU2018271862B2 (en) |
| CA (1) | CA3063976A1 (en) |
| MX (1) | MX2019013862A (en) |
| WO (1) | WO2018217787A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2608967T3 (en) | 2011-03-28 | 2017-04-17 | Mei Pharma, Inc. | (Aralkylamino substituted in alpha and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in the treatment of proliferative diseases |
| EP3630118A4 (en) * | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | Combination therapy |
| MA49921A (en) | 2017-08-14 | 2021-05-12 | Mei Pharma Inc | POLYTHERAPY |
| US20210161909A1 (en) * | 2018-08-14 | 2021-06-03 | Mei Pharma, Inc. | Combination therapy |
| EP4069302A1 (en) * | 2019-12-05 | 2022-10-12 | Sorrento Therapeutics, Inc. | Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic delivery device |
| TWI843159B (en) * | 2021-07-27 | 2024-05-21 | 大陸商廣州嘉越醫藥科技有限公司 | Drug combinations and their applications |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120252802A1 (en) * | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| WO2016010879A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711804A3 (en) | 1994-11-14 | 1999-09-22 | Ciba SC Holding AG | Latent light stabilizers |
| JP3512911B2 (en) | 1995-07-11 | 2004-03-31 | 富士写真フイルム株式会社 | Ultraviolet absorber precursor compound, photosensitive resin composition containing the same and image forming method |
| EP1020462B1 (en) | 1997-07-24 | 2004-02-11 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agent containing the same as active ingredient |
| JPH11174638A (en) | 1997-12-08 | 1999-07-02 | Konica Corp | Silver halide color photographic material |
| WO2001091699A2 (en) | 2000-05-30 | 2001-12-06 | Advanced Research & Technology Institute | Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways |
| JP3836436B2 (en) | 2001-04-27 | 2006-10-25 | 全薬工業株式会社 | Heterocyclic compounds and antitumor agents containing the same as active ingredients |
| DE10207037A1 (en) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | New 2-amino-4-(bicyclic substituted amino)-1,3,5-triazine derivatives, useful as pre- or post-emergence, total or selective herbicides or as plant growth regulators |
| DE60314603T2 (en) | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | COMPOSITIONS NECESSARY AS PROTEIN KINASE INHIBITORS |
| AU2003220299A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
| ATE433973T1 (en) | 2002-03-15 | 2009-07-15 | Vertex Pharma | AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES |
| EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
| AU2003231538A1 (en) | 2002-05-17 | 2003-12-02 | Kyowa Hakko Kogyo Co., Ltd. | Method of searching substane having antidiabetic activity |
| WO2004037812A1 (en) | 2002-10-25 | 2004-05-06 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient |
| KR101052482B1 (en) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 2,4,6-trisubstituted pyrimidine, a phosphatidylinositol (PI) 3-kinase inhibitor, and their use in the treatment of cancer |
| US7223759B2 (en) | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
| BRPI0506817A (en) | 2004-01-12 | 2007-05-29 | Cytopia Res Pty Ltd | selective kinase inhibitors |
| DK1741714T3 (en) | 2004-03-31 | 2013-04-15 | Zenyaku Kogyo Kk | Heterocyclic compound and anti-malignant turmeric agent containing this as active ingredient |
| PL1784396T3 (en) | 2004-08-26 | 2011-05-31 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| RU2443441C2 (en) | 2005-03-11 | 2012-02-27 | Зеняку Когио Кабусикикайся | Immunodepressant and anticancer drug containing heterocyclic compound as active ingredient |
| GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| US20070244110A1 (en) | 2006-04-14 | 2007-10-18 | Zenyaku Kogyo Kabushiki Kaisha | Treatment of prostate cancer, melanoma or hepatic cancer |
| DK2041139T3 (en) | 2006-04-26 | 2012-01-16 | Genentech Inc | Pharmaceutical compounds |
| AR060632A1 (en) | 2006-04-26 | 2008-07-02 | Genentech Inc | PHOSFOINOSITIDE INHIBITING COMPOUNDS 3- KINASE AND METHODS OF USE |
| NZ575274A (en) | 2006-08-08 | 2010-11-26 | Chugai Pharmaceutical Co Ltd | Pyrimidine derivative as pi3k inhibitor and use thereof |
| WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032027A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| JP2010503649A (en) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | Pyrimidine derivatives |
| WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EP2064203A1 (en) | 2006-09-14 | 2009-06-03 | AstraZeneca AB | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032077A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| JP2010503651A (en) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | 2-Benzimidazolyl-6-morpholino-phenylpyrimidine derivatives as PI3K and mTOR inhibitors for the treatment of proliferative disorders |
| JP2010503648A (en) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | 2-Benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine, or azepine) pyrimidine derivatives as PI3K and MTOR inhibitors for the treatment of proliferative diseases |
| WO2008032041A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| KR20090108124A (en) | 2007-02-06 | 2009-10-14 | 노파르티스 아게 | Pi 3-kinase inhibitors and methods of their use |
| US20080221103A1 (en) | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| CA2683152A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| AU2008273892A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| EP2209786B1 (en) | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| CA2706536C (en) | 2007-11-22 | 2016-04-19 | Tadaaki Sugama | Amorphous form of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| AP2010005346A0 (en) | 2008-01-15 | 2010-08-31 | Wyeth Llc | 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as mTOR kinase and P13 kinase inhibitors, and their synthesis. |
| WO2009093981A1 (en) | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
| US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
| TW200938201A (en) | 2008-02-07 | 2009-09-16 | Chugai Pharmaceutical Co Ltd | Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof |
| US20110053907A1 (en) | 2008-03-27 | 2011-03-03 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| PT3216793T (en) | 2008-05-23 | 2019-05-30 | Wyeth Llc | Triazine compounds as p13 kinase and mtor inhibitors |
| EP2310391A1 (en) | 2008-06-27 | 2011-04-20 | S*BIO Pte Ltd | Pyrazine substituted purines |
| JP2011527342A (en) | 2008-07-07 | 2011-10-27 | エックスカバリー ホールディング カンパニー エルエルシー | PI3K isoform selective inhibitor |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| KR101664511B1 (en) | 2008-11-13 | 2016-10-11 | 길리아드 칼리스토가 엘엘씨 | Therapies for hematologic malignancies |
| US20120165309A1 (en) | 2009-02-12 | 2012-06-28 | Astellas Pharma Inc. | Hetero ring derivative |
| WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
| MX2011010105A (en) | 2009-03-27 | 2012-01-12 | Pathway Therapeutics Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy. |
| CN102459272B (en) | 2009-05-27 | 2014-08-06 | 健泰科生物技术公司 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| SG182247A1 (en) | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| US8765940B2 (en) | 2009-06-25 | 2014-07-01 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2010151740A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2010266064A1 (en) | 2009-06-25 | 2012-01-19 | Amgen Inc. | 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors |
| WO2010151791A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| DK3072890T3 (en) * | 2009-07-07 | 2019-02-11 | Mei Pharma Inc | Pyrimidinyl and 1,3,5-triazinylbenzimidazoles and their use in cancer therapy |
| MX346042B (en) | 2010-08-10 | 2017-03-03 | Astellas Pharma Inc | Hetero ring compound. |
| JP2014500275A (en) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | Methods for treating baldness and for promoting hair growth |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| SG193984A1 (en) | 2011-03-28 | 2013-11-29 | Mei Pharma Inc | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| WO2012135166A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2014517079A (en) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
| JP2014520161A (en) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| JP6100274B2 (en) | 2011-11-11 | 2017-03-22 | メルク パテント ゲーエムベーハー | Process for the preparation of arylamines |
| EA029485B1 (en) | 2012-08-09 | 2018-04-30 | Селджин Корпорейшн | Methods of treating cancer selected from lymphoma, leukemia, myeloma, glioblastoma, colorectal cancer and hepatocellular carcinoma using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| WO2014055647A1 (en) | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| EP2832358A1 (en) | 2013-08-02 | 2015-02-04 | Bionsil S.r.l. | Pharmaceutical kit for use in the treatment of colon and colorectal cancer |
| CA2931431A1 (en) | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| AU2015220427B2 (en) | 2014-02-19 | 2017-09-21 | Piramal Enterprises Limited | Compounds for use as GPR120 agonists |
| WO2015193740A2 (en) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
| PT3179992T (en) | 2014-08-11 | 2022-07-12 | Acerta Pharma Bv | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| TW201618774A (en) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Methods of using BTK inhibitors to treat solid tumors and other diseases through modulation of the tumor microenvironment |
| ES2796903T3 (en) | 2014-09-23 | 2020-11-30 | Hoffmann La Roche | Procedure for the use of anti-CD79b immunoconjugates |
| US11261186B2 (en) | 2014-12-24 | 2022-03-01 | Lg Chem. Ltd. | Biaryl derivative as GPR120 agonist |
| IL305843B1 (en) | 2015-07-20 | 2024-09-01 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| CN108025191A (en) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | The method for the treatment of cancer |
| US20190054090A1 (en) * | 2015-10-01 | 2019-02-21 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| EP3487878A4 (en) | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| EP3630118A4 (en) * | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | Combination therapy |
| MA49921A (en) | 2017-08-14 | 2021-05-12 | Mei Pharma Inc | POLYTHERAPY |
| AU2019238207A1 (en) | 2018-03-21 | 2020-10-01 | Mei Pharma, Inc. | Combination therapy |
| US20210299134A1 (en) | 2018-08-14 | 2021-09-30 | Mei Pharma, Inc. | Treatment of b cell malignancies |
| MA53237A (en) | 2018-08-14 | 2021-06-23 | Mei Pharma Inc | TREATMENT OF RECURRING FOLLICULAR LYMPHOMA |
| TW202038945A (en) | 2018-12-21 | 2020-11-01 | 美商梅製藥公司 | Combination therapy |
-
2018
- 2018-05-22 EP EP18805258.3A patent/EP3630118A4/en active Pending
- 2018-05-22 US US16/613,638 patent/US11304953B2/en active Active
- 2018-05-22 CA CA3063976A patent/CA3063976A1/en active Pending
- 2018-05-22 MX MX2019013862A patent/MX2019013862A/en unknown
- 2018-05-22 AU AU2018271862A patent/AU2018271862B2/en active Active
- 2018-05-22 KR KR1020247020697A patent/KR20240097982A/en not_active Application Discontinuation
- 2018-05-22 JP JP2019564162A patent/JP2020521739A/en active Pending
- 2018-05-22 KR KR1020197038020A patent/KR20200009088A/en active Application Filing
- 2018-05-22 CN CN201880049740.0A patent/CN110996959A/en active Pending
- 2018-05-22 WO PCT/US2018/033936 patent/WO2018217787A1/en active Application Filing
- 2018-05-22 CN CN202410049431.0A patent/CN117860758A/en active Pending
-
2022
- 2022-03-01 US US17/684,306 patent/US20220193086A1/en active Pending
- 2022-11-11 JP JP2022181418A patent/JP2023022081A/en active Pending
-
2024
- 2024-01-26 JP JP2024010501A patent/JP2024056741A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120252802A1 (en) * | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| WO2016010879A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
Non-Patent Citations (6)
| Title |
|---|
| DAVIS RUTH J. ET AL,CANCER RESEARCH, US, (2017-03-31), vol. 77, no. 10, doi:10.1158/0008-5472.CAN-16-2534, ISSN 0008-5472, pages 2607 - 2619 * |
| DE HENAU OLIVIER ET AL, "Overcoming resistance to checkpoint blockade therapy by targeting P13K[gamma] in myeloid cells", NATURE, London, (2016-11-01), vol. 539, no. 7629, doi:10.1038/nature20554, ISSN 0028-0836, pages 443- 447 * |
| GULIDANNA SHAYAN ET AL, ONCOIMMUNOLOGY, US, (2016-12-07), vol. 6, no. 1, doi:10.1080/2162402X.2016.1261779, ISSN 2162-4011, pages 1 - 11 * |
| JIQING SAI ET AL, CLINICAL CANCER RESEARCH, US, (2016-12-21), vol. 23, no. 13, doi:10.1158/1078-0432.CCR-16-2142, ISSN 1078-0432, pages 3371 - 3384 * |
| LIU N ET AL, INTERNET CITATION, (2017-05-07), URL: https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2438_123, (2018-05-07) * |
| W. PENG ET AL, "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy", CANCER DISCOVERY, US, (2016-02-01), vol. 6, no. 2, doi:10.1158/2159-8290.CD-15-0283, ISSN 2159-8274, pages 202 - 216 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019013862A (en) | 2020-01-20 |
| JP2023022081A (en) | 2023-02-14 |
| US20220193086A1 (en) | 2022-06-23 |
| JP2020521739A (en) | 2020-07-27 |
| US11304953B2 (en) | 2022-04-19 |
| KR20240097982A (en) | 2024-06-27 |
| WO2018217787A1 (en) | 2018-11-29 |
| KR20200009088A (en) | 2020-01-29 |
| CN117860758A (en) | 2024-04-12 |
| EP3630118A1 (en) | 2020-04-08 |
| CN110996959A (en) | 2020-04-10 |
| EP3630118A4 (en) | 2021-03-31 |
| CA3063976A1 (en) | 2018-11-29 |
| JP2024056741A (en) | 2024-04-23 |
| US20200197403A1 (en) | 2020-06-25 |
| AU2018271862A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11713322B2 (en) | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | |
| AU2018271862B2 (en) | Combination therapy | |
| CA2943220C (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
| AU2017326558B2 (en) | Combination therapy | |
| US20140088103A1 (en) | (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | |
| WO2014055647A1 (en) | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases | |
| SG193984A1 (en) | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |